<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086460</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AA3-03</org_study_id>
    <nct_id>NCT03086460</nct_id>
  </id_info>
  <brief_title>A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)</brief_title>
  <acronym>FLASH</acronym>
  <official_title>A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI (Formoterol Fumarate) in Asthmatic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the dose-response of different doses of CHF 1531 pressurized metered dose inhaler&#xD;
      (pMDI) containing formoterol fumarate, on lung function and other clinical outcomes and to&#xD;
      identify the optimal dose(s) with regard to benefit/ risk ratio for further development in&#xD;
      the target subject population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, randomized, double-blind, placebo and active controlled dose-ranging, 6&#xD;
      arm incomplete block cross-over study to identify the optimal dose of CHF 1531 pMDI&#xD;
      (containing formoterol fumarate), with regard to lung function and other clinical efficacy&#xD;
      and safety outcome measures.&#xD;
&#xD;
      After a 2 week run-in period under rescue albuterol 'as needed' and background inhaled&#xD;
      corticosteroid (ICS), subjects qualifying for the study were required to complete 4 treatment&#xD;
      intervals of 2 weeks each, separated by 2 week wash-out intervals.&#xD;
&#xD;
      During each treatment interval, the subject were randomly assigned to take one of 5&#xD;
      double-blind study treatments twice daily (BID) i.e. one of 4 doses of CHF 1531 pMDI or a&#xD;
      matching placebo or the open-label active control treatment (Perforomist® Inhalation Solution&#xD;
      [IS]) also BID. During the entire study, all subjects concomitantly received ICS treatment&#xD;
      with QVAR® inhaler (beclomethasone dipropionate 40 or 80 µg /actuation) twice daily at a dose&#xD;
      that matches their pre-enrollment ICS and an albuterol inhaler to use as asthma rescue&#xD;
      medication on 'as needed' basis. The subjects visited the study center every 2 weeks to&#xD;
      undergo study procedures, and received a safety follow-up phone call one week after their&#xD;
      last visit. In total, the study lasted 18 weeks and required 10 visits to the study center.&#xD;
&#xD;
      During the study, daily asthma symptoms, peak expiratory flow, rescue and background&#xD;
      medication use, and compliance with the study medication were recorded in a subject diary.&#xD;
      Treatment-Emergent Adverse Events (TEAEs) were assessed and recorded throughout the study. A&#xD;
      full physical exam, routine hematology, blood chemistry, spirometry, vital signs measurement,&#xD;
      12-lead ECG, and pregnancy testing were performed before enrollment and at the end of the&#xD;
      study. Furthermore, on Day 1 and 14 of each treatment interval, serial spirometry, 12-lead&#xD;
      ECGs, blood pressure measurements (BP), serum potassium, and serum glucose were measured at&#xD;
      the study center for up to 12 hours post-dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2017</start_date>
  <completion_date type="Actual">July 28, 2018</completion_date>
  <primary_completion_date type="Actual">July 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 Area Under the Curve Between 0 and 12 h [AUC(0-12h)], Normalized by Time -- Change From Baseline to Post Dose Day 14</measure>
    <time_frame>Baseline, Day 14 post-dose</time_frame>
    <description>Spirometry used to measure FEV1, was performed according to internationally accepted standards. Results show the change from baseline in FEV1 AUC(0-12h), normalized by time on Day 14; it was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Definitions:&#xD;
AUC=Area under the curve; AUC(0-12h)=AUC between 0 and 12 h; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period; FEV1=Forced expiratory volume in the 1st second;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity Analysis 1: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14</measure>
    <time_frame>Baseline, Day 14 post-dose</time_frame>
    <description>The primary analysis was repeated, considering patients &quot;as randomized&quot; and including only the first instance of each treatment.&#xD;
Patients receiving the same treatment in more than one period were included in the analysis with only data from the first instance of each treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity Analysis 2: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14</measure>
    <time_frame>Baseline, Day 14 post-dose</time_frame>
    <description>The primary analysis was repeated, considering only patients and treatment periods for which treatment was assigned on or after the randomization error occurred.&#xD;
The number of patients shown represents those with at least one post-baseline assessment available.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity Analysis 3: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14</measure>
    <time_frame>Baseline, Day 14 post-dose</time_frame>
    <description>Patients receiving the same treatment during two treatment periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Patients considered in this analysis are those with at least one available post-baseline assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 1</measure>
    <time_frame>Baseline, Day 1 post-dose</time_frame>
    <description>Spirometry used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Spirometry used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Peak(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Spirometry, used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Morning FEV1 (L) -- Change From Baseline to Post Dose Day 14</measure>
    <time_frame>Baseline, Day 14 post-dose</time_frame>
    <description>Spirometry, used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Morning FVC -- Change From Baseline to Post Dose Day 14</measure>
    <time_frame>Baseline, Day 14 post-dose</time_frame>
    <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action -- Change From Baseline in Post-dose FEV1 ≥12% and ≥200 mL to Post Dose Day 1</measure>
    <time_frame>Baseline, Day 1 post-dose</time_frame>
    <description>Spirometry, used to measure FEV1, was performed according to internationally accepted standards.&#xD;
For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.&#xD;
Definitions:&#xD;
Time to onset of action=The time (in minutes) from receiving the study drug on Day 1, until the FEV1 change from baseline is ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving Onset of Action -- Change From Baseline in Post-dose FEV1 ≥12% and ≥200 mL to Post Dose Day 1</measure>
    <time_frame>Baseline, Day 1 post-dose</time_frame>
    <description>Patients achieving onset of action, defined as a change from baseline in post-dose FEV1 ≥12% and ≥200 mL, on Day 1. These are the subjects who contributed to the results, reported as median and 95% CI for 'Time to onset of action' presented in the Outcome Measure 13, above.&#xD;
For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.&#xD;
Definitions:&#xD;
Onset of action=Change from baseline in post-dose FEV1 ≥12% and ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) -- Change From Baseline for Post-dose on Day 1 and on Day 14</measure>
    <time_frame>Baseline, Day 1 and Day 14 post-dose</time_frame>
    <description>Vital signs -- Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) were measured at pre-specified times (at baseline - pre dose and on Day 14 of each treatment period or on the day of early study termination).&#xD;
Results are shown by treatment group, as change from baseline (in mmHg).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
Definitions:&#xD;
For safety variables, the baseline for each treatment period was defined as pre-dose measurements on Day 1 of each treatment period; Day 14=The day of the last dosing of a treatment period. Day 14 of the second, third, and fourth treatment periods (day of last dosing); treatments were separated by a 2-week wash-out interval;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG Parameter -- Heart Rate (HR) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Results are shown by treatment group, as change from baseline (in bpm).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) AUC(0-4h), Normalized by Time -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Heart rate HR AUC(0-4h) normalized by time. Results are shown by treatment group, as change from baseline (in bpm).&#xD;
The HR AUC(0-4h) normalized by time is calculated based on the actual times, using the linear trapezoidal rule.&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) Peak(0-4h), Normalized by Time -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Heart rate (HR) peak(0-4h) normalized by time.&#xD;
Results are shown by treatment group, as change from baseline (in bpm).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.&#xD;
Definitions:&#xD;
HR=Heart rate; HR peak(0-4h)=The maximum observed value over 4 hours following dosing;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) AUC(0-4h) and Peak(0-4h), Normalized by Time -- Change From Pre-dose to Post Dose Day 14</measure>
    <time_frame>Baseline, Day 14 post-dose</time_frame>
    <description>Heart rate (HR) AUC(0-4h) and HR peak(0-4h), normalized by time (in bpm).&#xD;
Results are shown as change from pre-dose on Day 14 (in bpm).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
Definitions:&#xD;
HR=Heart rate; HR AUC(0-4h)=Area under the curve between 0 and 4 h for heart rate; HR peak(0-4h)=The maximum observed value over 4 h after dosing;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead Electrocardiogram (ECG) Parameter (QTcF Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead Electrocardiogram (ECG) Parameter (PR Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead Electrocardiogram (ECG) Parameter (QRS Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Potassium -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Serum potassium level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Glucose -- Change From Baseline to Post-dose Day 1 and Day 14</measure>
    <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
    <description>Serum glucose level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A, CHF 1531 pMDI:&#xD;
CHF 1531 pMDI 6 μg total daily dose (TDD):&#xD;
1 inhalation of CHF 1531 pMDI 3 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B, CHF 1531 pMDI:&#xD;
CHF 1531 pMDI 12 μg TDD:&#xD;
1 inhalation of CHF 1531 pMDI 6 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C, CHF 1531 pMDI:&#xD;
CHF 1531 pMDI 24 μg TDD: 2 inhalations of CHF 1531 pMDI 6 μg/actuation BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment D, CHF 1531 pMDI&#xD;
CHF 1531 pMDI 48 μg TDD: 2 inhalations of CHF 1531 pMDI 12 μg/actuation BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment E, Matched placebo&#xD;
Placebo: 2 inhalations of CHF 1531 pMDI matched Placebo BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment F, Formoterol fumarate inhalation solution (IS)&#xD;
Perforomist® IS (active comparator, open-label) 40 μg TDD: 1 inhalation, 20 μg/ 2 mL vial, 1 vial BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1531 pMDI</intervention_name>
    <description>Dose Response: Test one of five different doses of CHF 1531</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Inhalation Solution</intervention_name>
    <description>Active Control</description>
    <arm_group_label>Treatment F</arm_group_label>
    <other_name>PERFOROMIST® 20 μg/ 2 mL vial, 1 vial BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pMDI</intervention_name>
    <description>Matched Placebo</description>
    <arm_group_label>Treatment E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects aged ≥18 and ≤75 years who have signed an Informed Consent&#xD;
             Form prior to initiation of any study-related procedure.&#xD;
&#xD;
          -  A diagnosis of asthma as defined in the Global Initiative for Asthma (GINA) Report,&#xD;
             2016, documented for at least 1 year prior to screening.&#xD;
&#xD;
          -  Poorly controlled or uncontrolled asthma evidenced by a score ≥1.5 on the Asthma&#xD;
             Control Questionnaire 7 © (ACQ-7)&#xD;
&#xD;
          -  A pre-bronchodilator Forced Expiratory Volume in the 1st Second ( FEV1) ≥60% and &lt;85%&#xD;
             of their predicted normal value, after appropriate washout from bronchodilators, at&#xD;
             the screening and randomization visits&#xD;
&#xD;
          -  Subjects with a positive response to a reversibility test at screening, defined as&#xD;
             change in FEV1 (ΔFEV1) ≥12% and ≥200 mL over baseline within 30 minutes after inhaling&#xD;
             4 puffs of albuterol hydrofluoroalkane(HFA) 90 µg/actuation.&#xD;
&#xD;
          -  Use of ICS (low/medium dose according to GINA Report, 2016) with or without a&#xD;
             long-acting bronchodilator for 3 months (at a stable dose in the last 4 weeks) before&#xD;
             screening visit.&#xD;
&#xD;
          -  A cooperative attitude and ability to demonstrate correct use of the diary, peak flow&#xD;
             meter, and pMDI inhaler.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women and all women physiologically capable of becoming pregnant&#xD;
             UNLESS they are willing to use a highly effective birth control methods&#xD;
&#xD;
          -  Subjects who suffer from Chronic Obstructive Pulmonary Disease (COPD) as defined by&#xD;
             the Global Strategy for Prevention, Diagnosis and Management of COPD (GOLD) Report,&#xD;
             2017, or are suspected of having Asthma COPD Overlap Syndrome (ACOS) as described in&#xD;
             the GINA Report, 2016.&#xD;
&#xD;
          -  Inability to carry out pulmonary function testing, to comply with study procedures or&#xD;
             with study drug intake.&#xD;
&#xD;
          -  Current smokers or ex-smokers (tobacco, vapor cigarettes, marijuana) with a smoking&#xD;
             history of &gt;10 pack-years or having stopped smoking one year or less prior to&#xD;
             screening visit.&#xD;
&#xD;
          -  History of life-threatening asthma, clinically significant uncontrolled disease or&#xD;
             respiratory infection.&#xD;
&#xD;
          -  An asthma exacerbation requiring oral/intravenous corticosteroids ≤ 30 days,&#xD;
             intramuscular depot corticosteroid ≤3 months or hospitalization within 6 months prior&#xD;
             to screening.&#xD;
&#xD;
          -  Subjects with unresolved bacterial or viral respiratory tract, sinus, or middle ear&#xD;
             infection affecting asthma status within 2 weeks prior to screening.&#xD;
&#xD;
          -  Subjects who received a vaccination within 2 weeks prior to screening or during the&#xD;
             run-in.&#xD;
&#xD;
          -  Subjects with oral candidiasis at screening and at randomization.&#xD;
&#xD;
          -  Subjects with any clinically significant, uncontrolled condition.&#xD;
&#xD;
          -  Subjects with serum potassium levels &lt;3.5 milliequivalents per litre (mEq/L) or (3.5&#xD;
             mmol/L) at screening.&#xD;
&#xD;
          -  Subjects who have clinically significant cardiovascular condition.&#xD;
&#xD;
          -  Subjects who have a clinically significant abnormal 12-lead ECG that results in active&#xD;
             medical problem which may impact the safety of the patient according to Investigator's&#xD;
             judgment.&#xD;
&#xD;
          -  Subjects whose 12-lead ECG shows Fridericia's corrected QT interval (QTcF) &gt;450 ms for&#xD;
             males or QTcF &gt;470 ms for females at screening or randomization visits.&#xD;
&#xD;
          -  Subjects with known intolerance/hypersensitivity or contra-indication to treatment&#xD;
             with inhaled β2-adrenergic receptor agonists, corticosteroids or propellant&#xD;
             gases/excipients.&#xD;
&#xD;
          -  Subjects with concomitant immunosuppressive therapy, use of oral or injected&#xD;
             corticosteroids, anti- Immunoglobulin E (IgE), anti-Interleukin 5 (IL5) or other&#xD;
             monoclonal or polyclonal antibodies within 12 weeks prior to screening.&#xD;
&#xD;
          -  Use of potent cytochrome P450 3A4 inhibitors and inducers within 4 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          -  History of alcohol abuse and/or substance/drug abuse within 12 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Subjects who have received an investigational drug within 1 month or 5 half-lives&#xD;
             (whichever is greater) prior to screening visit, or have been previously randomized in&#xD;
             this trial, or are currently participating in another clinical trial.&#xD;
&#xD;
          -  Subjects who are mentally or legally incapacitated or subjects accommodated in an&#xD;
             establishment as a result of an official or judicial order.&#xD;
&#xD;
          -  Subjects who have undergone major surgery in the 3 months prior to screening visit or&#xD;
             have a planned surgery during the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Sterling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sterling ENT, PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Investigational Site</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://goldcopd.org/</url>
    <description>Global Initiative for Chronic Obstructive Lung Disease, Inc. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease: 2017</description>
  </link>
  <link>
    <url>http://www.ginasthma.org</url>
    <description>Global Initiative for Asthma. Global strategy for asthma management and prevention (2016 update). 2016.</description>
  </link>
  <link>
    <url>https://www.cdc.gov/asthma/most_recent_data.htm</url>
    <description>Centers for Disease Control and Prevention: Asthma</description>
  </link>
  <link>
    <url>https://www.chiesi.com/en/air/</url>
    <description>Chiesi Farmaceutici S.p.A Respiratory</description>
  </link>
  <link>
    <url>https://www.chiesi.com/en/chiesi-farmaceutici-is-the-first-company-to-submit-a-marketing-authorisation-application-to-the-european-medicine-agency-for-a-triple-combination-for-the-treatment-of-copd-</url>
    <description>Chiesi Farmaceutici S.p.A - Press Release: Chiesi Farmaceutifici is the first company to submit a marketing authorisation application to the European Medicine Agency for a triple combination for the treatment of COPD</description>
  </link>
  <link>
    <url>http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/724/foradil-aerolizer-formoterol-fumarate-inhalation-powder</url>
    <description>CenterWatch: Foradil Aerolizer (formoterol fumarate inhalation powder)</description>
  </link>
  <link>
    <url>http://www.rtmagazine.com/2015/10/asthma-copd-foradil-aerolizer-to-be-discontinued/</url>
    <description>RT Magazine: Asthma-COPD Therapy Foradil Aerolizer to be Discontinued</description>
  </link>
  <reference>
    <citation>Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0. Erratum in: Lancet. 2013 Feb 23;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added].</citation>
    <PMID>23245604</PMID>
  </reference>
  <reference>
    <citation>Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010. Respir Res. 2013 Oct 9;14:103. doi: 10.1186/1465-9921-14-103.</citation>
    <PMID>24107140</PMID>
  </reference>
  <reference>
    <citation>Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002 May;121(5 Suppl):121S-126S. Review.</citation>
    <PMID>12010839</PMID>
  </reference>
  <reference>
    <citation>Tønnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013 Mar 1;22(127):37-43. doi: 10.1183/09059180.00007212. Review.</citation>
    <PMID>23457163</PMID>
  </reference>
  <reference>
    <citation>van Eerd EA, van der Meer RM, van Schayck OC, Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Aug 20;(8):CD010744. doi: 10.1002/14651858.CD010744.pub2. Review.</citation>
    <PMID>27545342</PMID>
  </reference>
  <reference>
    <citation>Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Oct 15;(10):CD010177. doi: 10.1002/14651858.CD010177.pub2. Review.</citation>
    <PMID>24127118</PMID>
  </reference>
  <reference>
    <citation>McGarvey L, Niewoehner D, Magder S, Sachs P, Tetzlaff K, Hamilton A, Korducki L, Bothner U, Vogelmeier C, Koch A, Ferguson GT. One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. COPD. 2015;12(5):484-93. doi: 10.3109/15412555.2014.991864. Epub 2015 Feb 18.</citation>
    <PMID>25692310</PMID>
  </reference>
  <reference>
    <citation>Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010 Jun;65(6):473-9. doi: 10.1136/thx.2009.125435.</citation>
    <PMID>20522841</PMID>
  </reference>
  <reference>
    <citation>Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012 Jan 22;72(2):273-300. doi: 10.2165/11208620-000000000-00000. Review.</citation>
    <PMID>22217233</PMID>
  </reference>
  <reference>
    <citation>Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005 Mar;127(3):809-17.</citation>
    <PMID>15764761</PMID>
  </reference>
  <reference>
    <citation>Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008;3(1):127-36.</citation>
    <PMID>18488436</PMID>
  </reference>
  <reference>
    <citation>Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD009285. doi: 10.1002/14651858.CD009285.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(7):CD009285.</citation>
    <PMID>22786525</PMID>
  </reference>
  <reference>
    <citation>Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.</citation>
    <PMID>27181606</PMID>
  </reference>
  <reference>
    <citation>Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002991. doi: 10.1002/14651858.CD002991.pub3. Review.</citation>
    <PMID>22786484</PMID>
  </reference>
  <reference>
    <citation>Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Mar 10;(3):CD010115. doi: 10.1002/14651858.CD010115.pub2. Review.</citation>
    <PMID>24615270</PMID>
  </reference>
  <reference>
    <citation>Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:295-304. doi: 10.2147/COPD.S42366. Epub 2013 Jun 27.</citation>
    <PMID>23836970</PMID>
  </reference>
  <reference>
    <citation>Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol. 2007 Mar;98(3):225-38.</citation>
    <PMID>17378253</PMID>
  </reference>
  <reference>
    <citation>Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004 Jul;126(1):213-9. Review.</citation>
    <PMID>15249465</PMID>
  </reference>
  <reference>
    <citation>Tashkin DP, Murray HE, Skeans M, Murray RP. Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest. 2004 Oct;126(4):1123-33.</citation>
    <PMID>15486373</PMID>
  </reference>
  <reference>
    <citation>Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009 Sep;34(3):641-7. doi: 10.1183/09031936.00193908. Epub 2009 May 14.</citation>
    <PMID>19443528</PMID>
  </reference>
  <reference>
    <citation>Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan;12(1):27-34. doi: 10.1513/AnnalsATS.201409-413OC.</citation>
    <PMID>25490706</PMID>
  </reference>
  <reference>
    <citation>Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016 Sep;4(9):731-741. doi: 10.1016/S2213-2600(16)30148-5. Epub 2016 Jul 23.</citation>
    <PMID>27460163</PMID>
  </reference>
  <reference>
    <citation>Johnell O, Pauwels R, Löfdahl CG, Laitinen LA, Postma DS, Pride NB, Ohlsson SV. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J. 2002 Jun;19(6):1058-63.</citation>
    <PMID>12108857</PMID>
  </reference>
  <reference>
    <citation>Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009 Dec;136(6):1456-1465. doi: 10.1378/chest.08-3016. Epub 2009 Jul 6.</citation>
    <PMID>19581353</PMID>
  </reference>
  <reference>
    <citation>Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011 Aug;66(8):699-708. doi: 10.1136/thx.2011.160028. Epub 2011 May 20. Review.</citation>
    <PMID>21602540</PMID>
  </reference>
  <reference>
    <citation>Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010 Nov;123(11):1001-6. doi: 10.1016/j.amjmed.2010.06.019. Epub 2010 Oct 1.</citation>
    <PMID>20870201</PMID>
  </reference>
  <reference>
    <citation>Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009 Apr;116(4):652-7. doi: 10.1016/j.ophtha.2008.12.001. Epub 2009 Feb 25.</citation>
    <PMID>19243828</PMID>
  </reference>
  <reference>
    <citation>Miller DP, Watkins SE, Sampson T, Davis KJ. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int J Chron Obstruct Pulmon Dis. 2011;6:467-76. doi: 10.2147/COPD.S14247. Epub 2011 Sep 16.</citation>
    <PMID>22003292</PMID>
  </reference>
  <reference>
    <citation>Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013 Mar;68(3):256-62. doi: 10.1136/thoraxjnl-2012-201772. Epub 2012 Jul 10.</citation>
    <PMID>22781123</PMID>
  </reference>
  <reference>
    <citation>Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.</citation>
    <PMID>17310045</PMID>
  </reference>
  <reference>
    <citation>Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of &quot;triple&quot; therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008 Jul;63(7):592-8. doi: 10.1136/thx.2007.087213. Epub 2008 Feb 1.</citation>
    <PMID>18245142</PMID>
  </reference>
  <reference>
    <citation>Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan;106(1):91-101. doi: 10.1016/j.rmed.2011.09.002. Epub 2011 Oct 29.</citation>
    <PMID>22040533</PMID>
  </reference>
  <reference>
    <citation>Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P, Frenzel C, Kurstjens N; Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015 Jun;70(6):519-27. doi: 10.1136/thoraxjnl-2014-206670. Epub 2015 Apr 3.</citation>
    <PMID>25841237</PMID>
  </reference>
  <reference>
    <citation>Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. COPD. 2016;13(1):1-10. doi: 10.3109/15412555.2015.1034256. Epub 2015 Oct 9.</citation>
    <PMID>26451734</PMID>
  </reference>
  <reference>
    <citation>Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1.</citation>
    <PMID>27598678</PMID>
  </reference>
  <reference>
    <citation>Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006 Jan;129(1):15-26. Erratum in: Chest. 2006 May;129(5):1393.</citation>
    <PMID>16424409</PMID>
  </reference>
  <reference>
    <citation>Wijesinghe M, Weatherall M, Perrin K, Harwood M, Beasley R. Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J. 2009 Oct;34(4):803-11. doi: 10.1183/09031936.00159708. Review.</citation>
    <PMID>19797669</PMID>
  </reference>
  <reference>
    <citation>Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010 Apr 1;362(13):1169-71. doi: 10.1056/NEJMp1002074. Epub 2010 Feb 24.</citation>
    <PMID>20181964</PMID>
  </reference>
  <reference>
    <citation>Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med. 2009 Apr 16;360(16):1671-2. doi: 10.1056/NEJMe0902057.</citation>
    <PMID>19369675</PMID>
  </reference>
  <reference>
    <citation>Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med. 2011 Jun 30;364(26):2473-5. doi: 10.1056/NEJMp1104375.</citation>
    <PMID>21714647</PMID>
  </reference>
  <reference>
    <citation>Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett AH, Prazma CM, Buaron KS, Pascoe SJ; AUSTRI Investigators. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. N Engl J Med. 2016 May 12;374(19):1822-30. doi: 10.1056/NEJMoa1511049. Epub 2016 Mar 6.</citation>
    <PMID>26949137</PMID>
  </reference>
  <reference>
    <citation>Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ; VESTRI Investigators. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. N Engl J Med. 2016 Sep 1;375(9):840-9. doi: 10.1056/NEJMoa1606356.</citation>
    <PMID>27579634</PMID>
  </reference>
  <reference>
    <citation>Novartis Pharma. FORADIL®AEROLIZER® US Prescribing Information. Whitehouse Station, New Jersey; 2012 Sep.</citation>
  </reference>
  <reference>
    <citation>Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrançois G. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration. 2005;72 Suppl 1:6-12.</citation>
    <PMID>15915007</PMID>
  </reference>
  <reference>
    <citation>Chiesi Farmaceutici S.p.A. A randomized, double blind, double dummy, single dose, crossover trial comparing the efficacy and safety of a single dose administered via 1 puff of 6 μg or 2 puffs of 6 μg of formoterol-HFA (pMDI) versus a single dose of 12 μg of formoterol- DPI (Foradil®Aerolizer®) and of placebo (pMDI or Aerolizer®) in moderate to severe asthmatic patients. RA/PR/3301/009/03.</citation>
  </reference>
  <reference>
    <citation>Bensch G, Lapidus RJ, Levine BE, Lumry W, Yegen U, Kiselev P, Della Cioppa G. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol. 2001 Jan;86(1):19-27.</citation>
    <PMID>11206232</PMID>
  </reference>
  <reference>
    <citation>Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma. 2003;40(5):505-14.</citation>
    <PMID>14529100</PMID>
  </reference>
  <reference>
    <citation>Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G; Formoterol in Chronic Obstructive Pulmonary Disease I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Sep 1;164(5):778-84.</citation>
    <PMID>11549532</PMID>
  </reference>
  <reference>
    <citation>Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G; Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002 Apr;121(4):1058-69.</citation>
    <PMID>11948033</PMID>
  </reference>
  <reference>
    <citation>Mylan Specialty L.P. PERFOROMIST® US Prescribing Information. Morgantown, West Virginia; 2013 Mar.</citation>
  </reference>
  <reference>
    <citation>Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K; Formoterol Study Group. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008 Feb;102(2):189-97.</citation>
    <PMID>18363201</PMID>
  </reference>
  <reference>
    <citation>Chiesi Farmaceutici S.p.A. CHF 1535 HFA : BDP + formoterol 100/6 μg pressurized inhalation solution : Common Technical Document. Module 2.5: 8.</citation>
  </reference>
  <reference>
    <citation>Bousquet J, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients. Respiration. 2005;72 Suppl 1:13-9.</citation>
    <PMID>15915008</PMID>
  </reference>
  <reference>
    <citation>Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5-40. Review.</citation>
    <PMID>8499054</PMID>
  </reference>
  <reference>
    <citation>Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, Poli G, Woodcock A. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol. 2004 Oct;58(4):359-66.</citation>
    <PMID>15373928</PMID>
  </reference>
  <reference>
    <citation>Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med. 2006 Apr;100(4):616-21. Epub 2005 Oct 13.</citation>
    <PMID>16226443</PMID>
  </reference>
  <reference>
    <citation>Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68.</citation>
    <PMID>16264058</PMID>
  </reference>
  <reference>
    <citation>Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M, Banerji D. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med. 2012 Dec 8;12:74. doi: 10.1186/1471-2466-12-74.</citation>
    <PMID>23217058</PMID>
  </reference>
  <reference>
    <citation>Center for Drug Evaluation and Research Medical Review. Clinical Team Leader Memorandum: Formoterol fumarate inhalation solution 20mcg/2mL; NDA # 22-007: 2007 Mar 15.</citation>
  </reference>
  <reference>
    <citation>Gross NJ, Kerwin E, Levine B, Kim KT, Denis-Mize K, Hamzavi M, Carpenter M, Rinehart M. Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Pulm Pharmacol Ther. 2008 Oct;21(5):818-23. doi: 10.1016/j.pupt.2008.07.002. Epub 2008 Jul 8.</citation>
    <PMID>18655841</PMID>
  </reference>
  <reference>
    <citation>Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999 Oct;14(4):902-7.</citation>
    <PMID>10573240</PMID>
  </reference>
  <reference>
    <citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38.</citation>
    <PMID>16055882</PMID>
  </reference>
  <reference>
    <citation>Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest. 2010 Jan;137(1):138-45. doi: 10.1378/chest.09-0919. Epub 2009 Sep 9.</citation>
    <PMID>19741060</PMID>
  </reference>
  <reference>
    <citation>Hankinson JL, Bang KM. Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population. Am Rev Respir Dis. 1991 Mar;143(3):516-21.</citation>
    <PMID>2001060</PMID>
  </reference>
  <reference>
    <citation>Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009 Jul 1;180(1):59-99. doi: 10.1164/rccm.200801-060ST.</citation>
    <PMID>19535666</PMID>
  </reference>
  <reference>
    <citation>Virchow JC, Backer V, de Blay F, Kuna P, Ljørring C, Prieto JL, Villesen HH. Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement. Respir Med. 2015 May;109(5):547-56. doi: 10.1016/j.rmed.2015.01.012. Epub 2015 Feb 3. Review.</citation>
    <PMID>25676887</PMID>
  </reference>
  <reference>
    <citation>Edwards D, Berry JJ. The efficiency of simulation-based multiple comparisons. Biometrics. 1987 Dec;43(4):913-28.</citation>
    <PMID>3427176</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <results_first_submitted>June 17, 2021</results_first_submitted>
  <results_first_submitted_qc>July 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2021</results_first_posted>
  <disposition_first_submitted>July 22, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>July 22, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 16, 2021</disposition_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03086460/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03086460/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult patients with confirmed diagnosis of asthma were recruited into the study according to the trial inclusion and exclusion criteria and were randomized into one of the 6 treatment groups. The total daily dose (TDD) of the trial investigational drug CHF 1531 pressurized metered dose Inhaler (pMDI), inhalation solution (IS) of the direct comparator, or matched placebo is indicated for each treatment group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study Group</title>
          <description>Each eligible patient was randomly assigned to one of the 12 treatments sequences. The study had an incomplete cross-over design. Patients were planned to take 4 out of 6 treatments, according to one of 12 possible sequences using a balanced incomplete block randomization scheme. Treatment intervals were separated by 2-week wash-out periods.&#xD;
For clarity, a summary of study participants who received treatment A, B, C, D, E, and F is presented below as milestones and also as periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Participants</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment A</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment B</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment C</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment D</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment E</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment F</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment C</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment D</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment E</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment F</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given period.</population>
      <group_list>
        <group group_id="B1">
          <title>Trial Participants</title>
          <description>All trial participants had diagnosed asthma and were randomized to 6 treatments in a cross-over study design.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.8" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since first diagnosis of asthma</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="335.2" lower_limit="80.8" upper_limit="810.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at first diagnosis of asthma</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.3" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma medication category at study entry</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Short-acting beta2-agonist (SABA [albuterol])</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukotriene modifiers (LTRM)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Theophylline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhaled corticosteroid (ICS) alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICS/Long-acting muscarinic antagonist (LABA), (free or fixed combination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICS/Long-acting muscarinic antagonist (LAMA), (free combination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICS/LABA/LAMA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking habits</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Current smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of smoking</title>
          <population>Only 9 trial participants had smoked (ex-smokers); thus, results on 9 participants are reported.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of pack-years</title>
          <population>Only 9 trial participants had smoked (ex-smokers).</population>
          <units>pack-years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" lower_limit="0.5" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 at screening (pre-bronchodilator)</title>
          <description>Measure description: Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath during the first second (i.e. FEV1) of the expiratory maneuver.</description>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.128" spread="0.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 % of the normal predicted value (pre-bronchodilator)</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 at screening (post-bronchodilator)</title>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.548" spread="0.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 % of the normal predicted value (post-bronchodilator)</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC at screening (pre-bronchodilator)</title>
          <description>Measure description: Forced vital capacity (FVC) is the maximal volume of gas that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible.</description>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.066" spread="0.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC at screening (post-bronchodilator)</title>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.450" spread="1.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reversibility FEV1 (mL) at screening</title>
          <units>millilitre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="420" spread="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reversibility FEV1 (%) at screening</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.1" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 Area Under the Curve Between 0 and 12 h [AUC(0-12h)], Normalized by Time -- Change From Baseline to Post Dose Day 14</title>
        <description>Spirometry used to measure FEV1, was performed according to internationally accepted standards. Results show the change from baseline in FEV1 AUC(0-12h), normalized by time on Day 14; it was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Definitions:&#xD;
AUC=Area under the curve; AUC(0-12h)=AUC between 0 and 12 h; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period; FEV1=Forced expiratory volume in the 1st second;</description>
        <time_frame>Baseline, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under the Curve Between 0 and 12 h [AUC(0-12h)], Normalized by Time -- Change From Baseline to Post Dose Day 14</title>
          <description>Spirometry used to measure FEV1, was performed according to internationally accepted standards. Results show the change from baseline in FEV1 AUC(0-12h), normalized by time on Day 14; it was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Definitions:&#xD;
AUC=Area under the curve; AUC(0-12h)=AUC between 0 and 12 h; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period; FEV1=Forced expiratory volume in the 1st second;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.174" lower_limit="0.141" upper_limit="0.208"/>
                    <measurement group_id="O2" value="0.221" lower_limit="0.186" upper_limit="0.257"/>
                    <measurement group_id="O3" value="0.197" lower_limit="0.161" upper_limit="0.232"/>
                    <measurement group_id="O4" value="0.231" lower_limit="0.199" upper_limit="0.263"/>
                    <measurement group_id="O5" value="0.064" lower_limit="0.030" upper_limit="0.098"/>
                    <measurement group_id="O6" value="0.208" lower_limit="0.175" upper_limit="0.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
The primary endpoint was analyzed using an analysis of covariance (ANCOVA) including treatment, period, and patient as fixed effects and baseline as a covariate. The confidence intervals (CIs) and the p-values of the comparisons between each dose of CHF 1531 pMDI and Placebo at Day 14 were adjusted for multiplicity, based on the parametric simulation method of Edwards and Berry.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.111</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.050</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.158</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.095</ci_lower_limit>
            <ci_upper_limit>0.220</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.133</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.194</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.167</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.109</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
The statistical analysis was performed using an analysis of covariance (ANCOVA) including treatment, period, and patient as fixed effects, and baseline as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.144</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
The statistical analysis was performed using an analysis of covariance (ANCOVA) including treatment, period, and patient as fixed effects, and baseline as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.022</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.102</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.340</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.075</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.690</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.038</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.155</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.082</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity Analysis 1: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14</title>
        <description>The primary analysis was repeated, considering patients &quot;as randomized&quot; and including only the first instance of each treatment.&#xD;
Patients receiving the same treatment in more than one period were included in the analysis with only data from the first instance of each treatment.</description>
        <time_frame>Baseline, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F,&#xD;
Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity Analysis 1: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14</title>
          <description>The primary analysis was repeated, considering patients &quot;as randomized&quot; and including only the first instance of each treatment.&#xD;
Patients receiving the same treatment in more than one period were included in the analysis with only data from the first instance of each treatment.</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.169" lower_limit="0.134" upper_limit="0.205"/>
                    <measurement group_id="O2" value="0.224" lower_limit="0.187" upper_limit="0.260"/>
                    <measurement group_id="O3" value="0.196" lower_limit="0.158" upper_limit="0.233"/>
                    <measurement group_id="O4" value="0.232" lower_limit="0.198" upper_limit="0.265"/>
                    <measurement group_id="O5" value="0.058" lower_limit="0.021" upper_limit="0.094"/>
                    <measurement group_id="O6" value="0.206" lower_limit="0.173" upper_limit="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
Analysis of covariance model: treatment, subject, and period as fixed effects; baseline FEV1 value as covariates. CIs and p-values for CHF 1531 pMDI vs Placebo are adjusted for multiplicity (parametric simulation method by Edwards and Berry). Subjects receiving the same treatment in more than one period are included in the primary efficacy model with only data from the first instance of each treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.049</ci_lower_limit>
            <ci_upper_limit>0.175</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.230</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.138</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.174</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.113</ci_lower_limit>
            <ci_upper_limit>0.235</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Analysis of covariance model: treatment, subject, and period as fixed effects; baseline FEV1 value as covariates. Subjects receiving the same treatment in more than one period are included in the primary efficacy model with only data from the first instance of each treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.197</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Analysis of covariance model: treatment, subject, and period as fixed effects; baseline FEV1 value as covariates. Subjects receiving the same treatment in more than one period are included in the primary efficacy model with only data from the first instance of each treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.054</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.104</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.301</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.062</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.294</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.028</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.080</ci_lower_limit>
            <ci_upper_limit>0.024</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.747</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.042</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.155</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity Analysis 2: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14</title>
        <description>The primary analysis was repeated, considering only patients and treatment periods for which treatment was assigned on or after the randomization error occurred.&#xD;
The number of patients shown represents those with at least one post-baseline assessment available.</description>
        <time_frame>Baseline, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F,&#xD;
Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity Analysis 2: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14</title>
          <description>The primary analysis was repeated, considering only patients and treatment periods for which treatment was assigned on or after the randomization error occurred.&#xD;
The number of patients shown represents those with at least one post-baseline assessment available.</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.129" lower_limit="0.089" upper_limit="0.170"/>
                    <measurement group_id="O2" value="0.180" lower_limit="0.136" upper_limit="0.223"/>
                    <measurement group_id="O3" value="0.159" lower_limit="0.116" upper_limit="0.201"/>
                    <measurement group_id="O4" value="0.179" lower_limit="0.141" upper_limit="0.217"/>
                    <measurement group_id="O5" value="-0.006" lower_limit="-0.047" upper_limit="0.034"/>
                    <measurement group_id="O6" value="0.170" lower_limit="0.129" upper_limit="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
Analysis of covariance model: treatment, subject, and period as fixed effects; baseline FEV1 value as covariates. CIs and p-values for CHF 1531 pMDI vs Placebo are adjusted for multiplicity (parametric simulation method by Edwards and Berry). Subjects receiving the same treatment in more than one period are included in the model with only data for the instance of each treatment, which occurred after the randomization error.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.065</ci_lower_limit>
            <ci_upper_limit>0.207</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.186</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.113</ci_lower_limit>
            <ci_upper_limit>0.258</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.165</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.092</ci_lower_limit>
            <ci_upper_limit>0.238</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.185</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.118</ci_lower_limit>
            <ci_upper_limit>0.252</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Analysis of covariance model: treatment, subject, and period as fixed effects; baseline FEV1 value as covariates. Subjects receiving the same treatment in more than one period are included in the model with only data for the instance of each treatment which occurred after the randomization error.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.176</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.121</ci_lower_limit>
            <ci_upper_limit>0.231</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Analysis of covariance model: treatment, subject, and period as fixed effects; baseline FEV1 value as covariates. Subjects receiving the same treatment in more than one period are included in the model with only data for the instance of each treatment which occurred after the randomization error.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.323</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.029</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.489</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.080</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.978</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.057</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.484</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.077</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity Analysis 3: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14</title>
        <description>Patients receiving the same treatment during two treatment periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Patients considered in this analysis are those with at least one available post-baseline assessment.</description>
        <time_frame>Baseline, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F,&#xD;
Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity Analysis 3: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14</title>
          <description>Patients receiving the same treatment during two treatment periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Patients considered in this analysis are those with at least one available post-baseline assessment.</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.144" lower_limit="0.103" upper_limit="0.186"/>
                    <measurement group_id="O2" value="0.194" lower_limit="0.151" upper_limit="0.237"/>
                    <measurement group_id="O3" value="0.170" lower_limit="0.128" upper_limit="0.213"/>
                    <measurement group_id="O4" value="0.198" lower_limit="0.157" upper_limit="0.238"/>
                    <measurement group_id="O5" value="0.037" lower_limit="-0.004" upper_limit="0.079"/>
                    <measurement group_id="O6" value="0.184" lower_limit="0.143" upper_limit="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
Analysis of covariance model: treatment and period as fixed effects, subject as random effect, baseline FEV1 value as covariate. CIs and p-values for CHF 1531 pMDI vs Placebo are adjusted for multiplicity (parametric simulation method by Edwards and Berry). Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.107</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.157</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.133</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.160</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Analysis of covariance model: treatment and period as fixed effects, subject as random effect, baseline FEV1 value as covariate. Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.147</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Analysis of covariance model: treatment and period as fixed effects, subject as random effect, baseline FEV1 value as covariate. Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.275</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.053</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.350</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.073</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.886</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.044</ci_lower_limit>
            <ci_upper_limit>0.051</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #6 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.254</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 1</title>
        <description>Spirometry used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
        <time_frame>Baseline, Day 1 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 1</title>
          <description>Spirometry used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.181" lower_limit="0.143" upper_limit="0.219"/>
                    <measurement group_id="O2" value="0.221" lower_limit="0.179" upper_limit="0.262"/>
                    <measurement group_id="O3" value="0.260" lower_limit="0.221" upper_limit="0.298"/>
                    <measurement group_id="O4" value="0.282" lower_limit="0.245" upper_limit="0.319"/>
                    <measurement group_id="O5" value="0.067" lower_limit="0.030" upper_limit="0.103"/>
                    <measurement group_id="O6" value="0.239" lower_limit="0.201" upper_limit="0.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
This secondary efficacy variable was analyzed using the ANCOVA model that was also used for the primary efficacy analysis, without adjusting for multiplicity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.114</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.060</ci_lower_limit>
            <ci_upper_limit>0.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.099</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.193</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.138</ci_lower_limit>
            <ci_upper_limit>0.247</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.216</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.163</ci_lower_limit>
            <ci_upper_limit>0.268</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.172</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.120</ci_lower_limit>
            <ci_upper_limit>0.224</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.165</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.016</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.024</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.101</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.049</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.187</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.097</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.062</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.116</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.406</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
        <description>Spirometry used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.&#xD;
Due to an error in the randomization system during the trial, some patients received the same treatment in several treatment period, as summarized in section Participant Flow.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
          <description>Spirometry used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.&#xD;
Due to an error in the randomization system during the trial, some patients received the same treatment in several treatment period, as summarized in section Participant Flow.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.220" lower_limit="0.180" upper_limit="0.260"/>
                    <measurement group_id="O2" value="0.250" lower_limit="0.207" upper_limit="0.293"/>
                    <measurement group_id="O3" value="0.270" lower_limit="0.229" upper_limit="0.311"/>
                    <measurement group_id="O4" value="0.317" lower_limit="0.279" upper_limit="0.356"/>
                    <measurement group_id="O5" value="0.047" lower_limit="0.009" upper_limit="0.085"/>
                    <measurement group_id="O6" value="0.288" lower_limit="0.249" upper_limit="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.214" lower_limit="0.174" upper_limit="0.254"/>
                    <measurement group_id="O2" value="0.251" lower_limit="0.210" upper_limit="0.293"/>
                    <measurement group_id="O3" value="0.231" lower_limit="0.190" upper_limit="0.273"/>
                    <measurement group_id="O4" value="0.278" lower_limit="0.241" upper_limit="0.316"/>
                    <measurement group_id="O5" value="0.061" lower_limit="0.021" upper_limit="0.101"/>
                    <measurement group_id="O6" value="0.259" lower_limit="0.221" upper_limit="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
This secondary efficacy variable was analyzed using the ANCOVA model that was also used for the primary efficacy analysis, without adjusting for multiplicity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.173</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.116</ci_lower_limit>
            <ci_upper_limit>0.230</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.203</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.146</ci_lower_limit>
            <ci_upper_limit>0.260</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.223</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.280</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.270</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.216</ci_lower_limit>
            <ci_upper_limit>0.325</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.241</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.187</ci_lower_limit>
            <ci_upper_limit>0.295</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.030</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.028</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.107</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.520</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.067</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.124</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.153</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.095</ci_lower_limit>
            <ci_upper_limit>0.210</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.190</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.131</ci_lower_limit>
            <ci_upper_limit>0.249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.170</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.113</ci_lower_limit>
            <ci_upper_limit>0.228</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.217</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.162</ci_lower_limit>
            <ci_upper_limit>0.272</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.198</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.144</ci_lower_limit>
            <ci_upper_limit>0.252</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.203</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.542</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.064</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.510</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.080</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.352</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.084</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Peak(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
        <description>Spirometry, used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Peak(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
          <description>Spirometry, used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.359" lower_limit="0.317" upper_limit="0.401"/>
                    <measurement group_id="O2" value="0.370" lower_limit="0.326" upper_limit="0.414"/>
                    <measurement group_id="O3" value="0.393" lower_limit="0.351" upper_limit="0.436"/>
                    <measurement group_id="O4" value="0.430" lower_limit="0.390" upper_limit="0.470"/>
                    <measurement group_id="O5" value="0.178" lower_limit="0.138" upper_limit="0.218"/>
                    <measurement group_id="O6" value="0.416" lower_limit="0.375" upper_limit="0.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.346" lower_limit="0.303" upper_limit="0.390"/>
                    <measurement group_id="O2" value="0.373" lower_limit="0.328" upper_limit="0.419"/>
                    <measurement group_id="O3" value="0.349" lower_limit="0.304" upper_limit="0.394"/>
                    <measurement group_id="O4" value="0.389" lower_limit="0.348" upper_limit="0.430"/>
                    <measurement group_id="O5" value="0.183" lower_limit="0.140" upper_limit="0.227"/>
                    <measurement group_id="O6" value="0.367" lower_limit="0.325" upper_limit="0.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
This secondary efficacy variable was analyzed using the ANCOVA model that was also used for the primary efficacy analysis, without adjusting for multiplicity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.181</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.122</ci_lower_limit>
            <ci_upper_limit>0.241</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.192</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.133</ci_lower_limit>
            <ci_upper_limit>0.251</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.275</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.252</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.195</ci_lower_limit>
            <ci_upper_limit>0.309</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.238</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.182</ci_lower_limit>
            <ci_upper_limit>0.295</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.723</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.011</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.257</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.093</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.071</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.128</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.464</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.060</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.219</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.163</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.100</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.190</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.126</ci_lower_limit>
            <ci_upper_limit>0.254</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.229</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.206</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.146</ci_lower_limit>
            <ci_upper_limit>0.266</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.184</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.125</ci_lower_limit>
            <ci_upper_limit>0.243</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.400</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.931</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.160</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.043</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.102</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.464</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.090</ci_lower_limit>
            <ci_upper_limit>0.041</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.623</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.047</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.197</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
        <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
          <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.111" lower_limit="0.068" upper_limit="0.154"/>
                    <measurement group_id="O2" value="0.156" lower_limit="0.109" upper_limit="0.203"/>
                    <measurement group_id="O3" value="0.160" lower_limit="0.116" upper_limit="0.204"/>
                    <measurement group_id="O4" value="0.182" lower_limit="0.140" upper_limit="0.224"/>
                    <measurement group_id="O5" value="0.059" lower_limit="0.018" upper_limit="0.100"/>
                    <measurement group_id="O6" value="0.172" lower_limit="0.128" upper_limit="0.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.103" lower_limit="0.064" upper_limit="0.142"/>
                    <measurement group_id="O2" value="0.134" lower_limit="0.093" upper_limit="0.174"/>
                    <measurement group_id="O3" value="0.120" lower_limit="0.079" upper_limit="0.160"/>
                    <measurement group_id="O4" value="0.142" lower_limit="0.105" upper_limit="0.178"/>
                    <measurement group_id="O5" value="0.060" lower_limit="0.020" upper_limit="0.099"/>
                    <measurement group_id="O6" value="0.134" lower_limit="0.096" upper_limit="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
This secondary efficacy variable was analyzed using the ANCOVA model that was also used for the primary efficacy analysis, without adjusting for multiplicity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.052</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.159</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.101</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.163</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.122</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.054</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.117</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.071</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.130</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.909</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.062</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.419</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.483</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.022</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.126</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.043</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.074</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.060</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.116</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.074</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.127</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.282</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.031</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.554</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.149</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.091</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.636</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.072</ci_lower_limit>
            <ci_upper_limit>0.044</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.775</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.047</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.425</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.022</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.077</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
        <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
          <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.158" lower_limit="0.112" upper_limit="0.203"/>
                    <measurement group_id="O2" value="0.186" lower_limit="0.136" upper_limit="0.235"/>
                    <measurement group_id="O3" value="0.159" lower_limit="0.113" upper_limit="0.206"/>
                    <measurement group_id="O4" value="0.215" lower_limit="0.171" upper_limit="0.260"/>
                    <measurement group_id="O5" value="0.036" lower_limit="-0.007" upper_limit="0.079"/>
                    <measurement group_id="O6" value="0.213" lower_limit="0.168" upper_limit="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.135" lower_limit="0.089" upper_limit="0.181"/>
                    <measurement group_id="O2" value="0.146" lower_limit="0.098" upper_limit="0.195"/>
                    <measurement group_id="O3" value="0.136" lower_limit="0.089" upper_limit="0.184"/>
                    <measurement group_id="O4" value="0.194" lower_limit="0.151" upper_limit="0.238"/>
                    <measurement group_id="O5" value="0.050" lower_limit="0.004" upper_limit="0.095"/>
                    <measurement group_id="O6" value="0.177" lower_limit="0.132" upper_limit="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
This secondary efficacy variable was analyzed using the ANCOVA model that was also used for the primary efficacy analysis, without adjusting for multiplicity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.122</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.058</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.150</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.215</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.124</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.189</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.180</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.118</ci_lower_limit>
            <ci_upper_limit>0.242</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.177</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.115</ci_lower_limit>
            <ci_upper_limit>0.238</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.410</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.028</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.961</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.063</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.454</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.095</ci_lower_limit>
            <ci_upper_limit>0.043</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.370</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.030</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.086</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.056</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.086</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.029</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.087</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.145</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.127</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.065</ci_lower_limit>
            <ci_upper_limit>0.189</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.740</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.011</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.055</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.973</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.064</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.059</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.774</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.079</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.076</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.058</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
        <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14</title>
          <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.331" lower_limit="0.277" upper_limit="0.384"/>
                    <measurement group_id="O2" value="0.347" lower_limit="0.290" upper_limit="0.404"/>
                    <measurement group_id="O3" value="0.354" lower_limit="0.299" upper_limit="0.408"/>
                    <measurement group_id="O4" value="0.367" lower_limit="0.315" upper_limit="0.419"/>
                    <measurement group_id="O5" value="0.216" lower_limit="0.166" upper_limit="0.267"/>
                    <measurement group_id="O6" value="0.385" lower_limit="0.333" upper_limit="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.310" lower_limit="0.259" upper_limit="0.361"/>
                    <measurement group_id="O2" value="0.331" lower_limit="0.277" upper_limit="0.385"/>
                    <measurement group_id="O3" value="0.304" lower_limit="0.251" upper_limit="0.358"/>
                    <measurement group_id="O4" value="0.350" lower_limit="0.301" upper_limit="0.399"/>
                    <measurement group_id="O5" value="0.198" lower_limit="0.147" upper_limit="0.250"/>
                    <measurement group_id="O6" value="0.340" lower_limit="0.290" upper_limit="0.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
This secondary efficacy variable was analyzed using the ANCOVA model that was also used for the primary efficacy analysis, without adjusting for multiplicity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.114</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.130</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.206</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.137</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.213</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.151</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.168</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.240</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.679</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.061</ci_lower_limit>
            <ci_upper_limit>0.093</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.549</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.052</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.323</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.866</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.007</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.073</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.596</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.055</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</non_inferiority_desc>
            <p_value>0.720</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.061</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.133</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.209</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.106</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>0.180</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.152</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.142</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.212</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.573</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.053</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.881</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.006</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.078</ci_lower_limit>
            <ci_upper_limit>0.067</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.261</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.493</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.104</ci_lower_limit>
            <ci_upper_limit>0.051</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.616</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.019</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.055</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.046</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Morning FEV1 (L) -- Change From Baseline to Post Dose Day 14</title>
        <description>Spirometry, used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
        <time_frame>Baseline, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Morning FEV1 (L) -- Change From Baseline to Post Dose Day 14</title>
          <description>Spirometry, used to measure FEV1, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.071" lower_limit="0.021" upper_limit="0.120"/>
                    <measurement group_id="O2" value="0.102" lower_limit="0.049" upper_limit="0.155"/>
                    <measurement group_id="O3" value="0.073" lower_limit="0.021" upper_limit="0.125"/>
                    <measurement group_id="O4" value="0.149" lower_limit="0.101" upper_limit="0.197"/>
                    <measurement group_id="O5" value="0.037" lower_limit="-0.013" upper_limit="0.087"/>
                    <measurement group_id="O6" value="0.126" lower_limit="0.077" upper_limit="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
This secondary efficacy variable was analyzed using the ANCOVA model that was also used for the primary efficacy analysis, without adjusting for multiplicity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.065</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.328</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.089</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.404</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.031</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.042</ci_lower_limit>
            <ci_upper_limit>0.104</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.942</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.069</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.147</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.463</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.028</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.104</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.076</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Morning FVC -- Change From Baseline to Post Dose Day 14</title>
        <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
        <time_frame>Baseline, Day 14 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Morning FVC -- Change From Baseline to Post Dose Day 14</title>
          <description>Spirometry, used to measure FVC, was performed according to internationally accepted standards.&#xD;
Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).&#xD;
Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" lower_limit="-0.005" upper_limit="0.102"/>
                    <measurement group_id="O2" value="0.044" lower_limit="-0.013" upper_limit="0.101"/>
                    <measurement group_id="O3" value="0.048" lower_limit="-0.009" upper_limit="0.104"/>
                    <measurement group_id="O4" value="0.114" lower_limit="0.062" upper_limit="0.166"/>
                    <measurement group_id="O5" value="0.053" lower_limit="-0.000" upper_limit="0.107"/>
                    <measurement group_id="O6" value="0.114" lower_limit="0.061" upper_limit="0.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
This secondary efficacy variable was analyzed using the ANCOVA model that was also used for the primary efficacy analysis, without adjusting for multiplicity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.896</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.083</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.810</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.089</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.882</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.006</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.084</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.115</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.060</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.060</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.134</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.911</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.083</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.985</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.078</ci_lower_limit>
            <ci_upper_limit>0.077</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.066</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.928</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.078</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.078</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.070</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 14&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.089</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.066</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action -- Change From Baseline in Post-dose FEV1 ≥12% and ≥200 mL to Post Dose Day 1</title>
        <description>Spirometry, used to measure FEV1, was performed according to internationally accepted standards.&#xD;
For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.&#xD;
Definitions:&#xD;
Time to onset of action=The time (in minutes) from receiving the study drug on Day 1, until the FEV1 change from baseline is ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
        <time_frame>Baseline, Day 1 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action -- Change From Baseline in Post-dose FEV1 ≥12% and ≥200 mL to Post Dose Day 1</title>
          <description>Spirometry, used to measure FEV1, was performed according to internationally accepted standards.&#xD;
For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.&#xD;
Definitions:&#xD;
Time to onset of action=The time (in minutes) from receiving the study drug on Day 1, until the FEV1 change from baseline is ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358.8" lower_limit="43.1" upper_limit="NA">NA: Censoring for patients not achieving onset of action</measurement>
                    <measurement group_id="O2" value="60.3" lower_limit="31.3" upper_limit="NA">NA: Censoring for patients not achieving onset of action</measurement>
                    <measurement group_id="O3" value="33.6" lower_limit="16.0" upper_limit="118.8"/>
                    <measurement group_id="O4" value="44.3" lower_limit="16.0" upper_limit="240.1"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">NA: Censoring for patients not achieving onset of action</measurement>
                    <measurement group_id="O6" value="45.5" lower_limit="32.6" upper_limit="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment A (CHF 1531 pMDI 6 μg TDD) versus Treatment E (Placebo).&#xD;
Time to onset of action was analyzed using a Cox proportional hazard model stratified by patient, including treatment and period as a factor, and baseline FEV1 as covariate.&#xD;
For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>18.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.25</ci_lower_limit>
            <ci_upper_limit>76.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>31.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.52</ci_lower_limit>
            <ci_upper_limit>133.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>44.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.23</ci_lower_limit>
            <ci_upper_limit>191.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>40.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.54</ci_lower_limit>
            <ci_upper_limit>170.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment F ( Perforomist® IS 40 μg TDD) versus Treatment E (Placebo).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>22.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.70</ci_lower_limit>
            <ci_upper_limit>92.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment B (CHF 1531 pMDI 12 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.195</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>4.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Regression, Cox</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>5.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment A (CHF 1531 pMDI 6 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>4.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment C (CHF 1531 pMDI 24 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.435</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>3.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment B (CHF 1531 pMDI 12 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.564</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 1&#xD;
Comparison groups were:&#xD;
Treatment D (CHF 1531 pMDI 48 μg TDD) versus Treatment C (CHF 1531 pMDI 24 μg TDD).&#xD;
Statistical analysis was performed as described for the statistical analysis #1 of this outcome measure.</non_inferiority_desc>
            <p_value>0.818</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving Onset of Action -- Change From Baseline in Post-dose FEV1 ≥12% and ≥200 mL to Post Dose Day 1</title>
        <description>Patients achieving onset of action, defined as a change from baseline in post-dose FEV1 ≥12% and ≥200 mL, on Day 1. These are the subjects who contributed to the results, reported as median and 95% CI for 'Time to onset of action' presented in the Outcome Measure 13, above.&#xD;
For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.&#xD;
Definitions:&#xD;
Onset of action=Change from baseline in post-dose FEV1 ≥12% and ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose);</description>
        <time_frame>Baseline, Day 1 post-dose</time_frame>
        <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Onset of Action -- Change From Baseline in Post-dose FEV1 ≥12% and ≥200 mL to Post Dose Day 1</title>
          <description>Patients achieving onset of action, defined as a change from baseline in post-dose FEV1 ≥12% and ≥200 mL, on Day 1. These are the subjects who contributed to the results, reported as median and 95% CI for 'Time to onset of action' presented in the Outcome Measure 13, above.&#xD;
For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.&#xD;
Definitions:&#xD;
Onset of action=Change from baseline in post-dose FEV1 ≥12% and ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose);</description>
          <population>Intention-to-treat (ITT): All randomized patients who received at least one dose of the study treatment within the given treatment period and with at least one available evaluation of efficacy (primary or secondary efficacy variables) after the baseline and within the given treatment period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) -- Change From Baseline for Post-dose on Day 1 and on Day 14</title>
        <description>Vital signs -- Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) were measured at pre-specified times (at baseline - pre dose and on Day 14 of each treatment period or on the day of early study termination).&#xD;
Results are shown by treatment group, as change from baseline (in mmHg).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
Definitions:&#xD;
For safety variables, the baseline for each treatment period was defined as pre-dose measurements on Day 1 of each treatment period; Day 14=The day of the last dosing of a treatment period. Day 14 of the second, third, and fourth treatment periods (day of last dosing); treatments were separated by a 2-week wash-out interval;</description>
        <time_frame>Baseline, Day 1 and Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) -- Change From Baseline for Post-dose on Day 1 and on Day 14</title>
          <description>Vital signs -- Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) were measured at pre-specified times (at baseline - pre dose and on Day 14 of each treatment period or on the day of early study termination).&#xD;
Results are shown by treatment group, as change from baseline (in mmHg).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
Definitions:&#xD;
For safety variables, the baseline for each treatment period was defined as pre-dose measurements on Day 1 of each treatment period; Day 14=The day of the last dosing of a treatment period. Day 14 of the second, third, and fourth treatment periods (day of last dosing); treatments were separated by a 2-week wash-out interval;</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Day 1, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-14" upper_limit="9"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-23" upper_limit="11"/>
                    <measurement group_id="O3" value="-0.8" lower_limit="-35" upper_limit="19"/>
                    <measurement group_id="O4" value="-1.2" lower_limit="-21" upper_limit="17"/>
                    <measurement group_id="O5" value="-0.5" lower_limit="-12" upper_limit="9"/>
                    <measurement group_id="O6" value="-0.8" lower_limit="-15" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 1 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-15" upper_limit="17"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-18" upper_limit="14"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-31" upper_limit="11"/>
                    <measurement group_id="O4" value="-0.6" lower_limit="-18" upper_limit="15"/>
                    <measurement group_id="O5" value="-0.8" lower_limit="-17" upper_limit="16"/>
                    <measurement group_id="O6" value="-0.8" lower_limit="-13" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 4 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="-11" upper_limit="20"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-13" upper_limit="15"/>
                    <measurement group_id="O3" value="-0.9" lower_limit="-32" upper_limit="16"/>
                    <measurement group_id="O4" value="0.9" lower_limit="-12" upper_limit="17"/>
                    <measurement group_id="O5" value="0.2" lower_limit="-14" upper_limit="17"/>
                    <measurement group_id="O6" value="0.5" lower_limit="-25" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 8 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-16" upper_limit="18"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-19" upper_limit="19"/>
                    <measurement group_id="O3" value="1.1" lower_limit="-23" upper_limit="31"/>
                    <measurement group_id="O4" value="0.7" lower_limit="-15" upper_limit="13"/>
                    <measurement group_id="O5" value="0.5" lower_limit="-18" upper_limit="14"/>
                    <measurement group_id="O6" value="2.5" lower_limit="-13" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 12 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="-13" upper_limit="21"/>
                    <measurement group_id="O2" value="2.1" lower_limit="-17" upper_limit="18"/>
                    <measurement group_id="O3" value="3.0" lower_limit="-24" upper_limit="28"/>
                    <measurement group_id="O4" value="1.4" lower_limit="-11" upper_limit="18"/>
                    <measurement group_id="O5" value="-0.1" lower_limit="-16" upper_limit="16"/>
                    <measurement group_id="O6" value="3.4" lower_limit="-12" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 14, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-15" upper_limit="15"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-19" upper_limit="20"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-17" upper_limit="23"/>
                    <measurement group_id="O4" value="-0.4" lower_limit="-22" upper_limit="23"/>
                    <measurement group_id="O5" value="-2.5" lower_limit="-19" upper_limit="22"/>
                    <measurement group_id="O6" value="-0.3" lower_limit="-14" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 14, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-23" upper_limit="23"/>
                    <measurement group_id="O2" value="-3.1" lower_limit="-24" upper_limit="15"/>
                    <measurement group_id="O3" value="-0.7" lower_limit="-25" upper_limit="24"/>
                    <measurement group_id="O4" value="-0.7" lower_limit="-27" upper_limit="36"/>
                    <measurement group_id="O5" value="-3.6" lower_limit="-16" upper_limit="15"/>
                    <measurement group_id="O6" value="-2.5" lower_limit="-19" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 14, 1 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-17" upper_limit="16"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-29" upper_limit="25"/>
                    <measurement group_id="O3" value="-1.8" lower_limit="-29" upper_limit="36"/>
                    <measurement group_id="O4" value="-1.9" lower_limit="-29" upper_limit="33"/>
                    <measurement group_id="O5" value="-1.7" lower_limit="-18" upper_limit="12"/>
                    <measurement group_id="O6" value="-1.1" lower_limit="-14" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 14, 4 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="-26" upper_limit="19"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-26" upper_limit="26"/>
                    <measurement group_id="O3" value="-1.4" lower_limit="-20" upper_limit="15"/>
                    <measurement group_id="O4" value="1.0" lower_limit="-13" upper_limit="25"/>
                    <measurement group_id="O5" value="-0.5" lower_limit="-26" upper_limit="49"/>
                    <measurement group_id="O6" value="-0.8" lower_limit="-20" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 14, 8 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-20" upper_limit="23"/>
                    <measurement group_id="O2" value="1.3" lower_limit="-13" upper_limit="16"/>
                    <measurement group_id="O3" value="1.1" lower_limit="-20" upper_limit="25"/>
                    <measurement group_id="O4" value="0.6" lower_limit="-16" upper_limit="28"/>
                    <measurement group_id="O5" value="-3.3" lower_limit="-27" upper_limit="27"/>
                    <measurement group_id="O6" value="0.6" lower_limit="-13" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 14, 12 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-18" upper_limit="17"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-23" upper_limit="29"/>
                    <measurement group_id="O3" value="1.5" lower_limit="-26" upper_limit="26"/>
                    <measurement group_id="O4" value="4.4" lower_limit="-18" upper_limit="39"/>
                    <measurement group_id="O5" value="-0.3" lower_limit="-20" upper_limit="43"/>
                    <measurement group_id="O6" value="2.5" lower_limit="-11" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-19" upper_limit="10"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-19" upper_limit="10"/>
                    <measurement group_id="O3" value="-1.2" lower_limit="-21" upper_limit="8"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-20" upper_limit="13"/>
                    <measurement group_id="O5" value="-0.3" lower_limit="-11" upper_limit="14"/>
                    <measurement group_id="O6" value="-1.2" lower_limit="-17" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 1 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-8" upper_limit="9"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-18" upper_limit="12"/>
                    <measurement group_id="O3" value="-0.4" lower_limit="-14" upper_limit="17"/>
                    <measurement group_id="O4" value="-1.6" lower_limit="-17" upper_limit="11"/>
                    <measurement group_id="O5" value="-2.5" lower_limit="-12" upper_limit="8"/>
                    <measurement group_id="O6" value="-1.7" lower_limit="-15" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 4 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-11" upper_limit="9"/>
                    <measurement group_id="O2" value="-1.4" lower_limit="-13" upper_limit="9"/>
                    <measurement group_id="O3" value="-0.4" lower_limit="-11" upper_limit="14"/>
                    <measurement group_id="O4" value="-1.0" lower_limit="-20" upper_limit="15"/>
                    <measurement group_id="O5" value="-1.6" lower_limit="-13" upper_limit="8"/>
                    <measurement group_id="O6" value="-1.0" lower_limit="-16" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 8 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-15" upper_limit="10"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-10" upper_limit="15"/>
                    <measurement group_id="O3" value="-0.4" lower_limit="-13" upper_limit="10"/>
                    <measurement group_id="O4" value="-1.9" lower_limit="-16" upper_limit="11"/>
                    <measurement group_id="O5" value="-1.7" lower_limit="-13" upper_limit="9"/>
                    <measurement group_id="O6" value="0.4" lower_limit="-17" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 12 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-11" upper_limit="16"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-14" upper_limit="15"/>
                    <measurement group_id="O3" value="0.4" lower_limit="-14" upper_limit="11"/>
                    <measurement group_id="O4" value="-1.0" lower_limit="-11" upper_limit="14"/>
                    <measurement group_id="O5" value="-0.3" lower_limit="-14" upper_limit="9"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-13" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 14, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-13" upper_limit="8"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-10" upper_limit="19"/>
                    <measurement group_id="O3" value="1.1" lower_limit="-13" upper_limit="10"/>
                    <measurement group_id="O4" value="-0.1" lower_limit="-16" upper_limit="14"/>
                    <measurement group_id="O5" value="-0.6" lower_limit="-13" upper_limit="10"/>
                    <measurement group_id="O6" value="-0.7" lower_limit="-13" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 14, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-14" upper_limit="17"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-21" upper_limit="20"/>
                    <measurement group_id="O3" value="-0.8" lower_limit="-20" upper_limit="8"/>
                    <measurement group_id="O4" value="-2.9" lower_limit="-20" upper_limit="16"/>
                    <measurement group_id="O5" value="-1.5" lower_limit="-12" upper_limit="10"/>
                    <measurement group_id="O6" value="-2.0" lower_limit="-14" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 14, 1 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-13" upper_limit="13"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-24" upper_limit="24"/>
                    <measurement group_id="O3" value="-0.5" lower_limit="-14" upper_limit="12"/>
                    <measurement group_id="O4" value="-2.4" lower_limit="-24" upper_limit="25"/>
                    <measurement group_id="O5" value="-1.8" lower_limit="-12" upper_limit="16"/>
                    <measurement group_id="O6" value="-1.6" lower_limit="-18" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 14, 4 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-15" upper_limit="9"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-18" upper_limit="19"/>
                    <measurement group_id="O3" value="-1.7" lower_limit="-12" upper_limit="9"/>
                    <measurement group_id="O4" value="-2.5" lower_limit="-17" upper_limit="10"/>
                    <measurement group_id="O5" value="0.4" lower_limit="-12" upper_limit="24"/>
                    <measurement group_id="O6" value="-2.3" lower_limit="-16" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 14, 8 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-15" upper_limit="15"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-18" upper_limit="18"/>
                    <measurement group_id="O3" value="0.3" lower_limit="-11" upper_limit="13"/>
                    <measurement group_id="O4" value="-2.6" lower_limit="-20" upper_limit="14"/>
                    <measurement group_id="O5" value="-1.7" lower_limit="-19" upper_limit="15"/>
                    <measurement group_id="O6" value="-1.3" lower_limit="-14" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 14, 12 h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-11" upper_limit="18"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-15" upper_limit="21"/>
                    <measurement group_id="O3" value="0.7" lower_limit="-10" upper_limit="13"/>
                    <measurement group_id="O4" value="-0.6" lower_limit="-19" upper_limit="14"/>
                    <measurement group_id="O5" value="1.4" lower_limit="-15" upper_limit="25"/>
                    <measurement group_id="O6" value="-0.1" lower_limit="-10" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-lead ECG Parameter -- Heart Rate (HR) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
        <description>Results are shown by treatment group, as change from baseline (in bpm).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>12-lead ECG Parameter -- Heart Rate (HR) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
          <description>Results are shown by treatment group, as change from baseline (in bpm).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-14" upper_limit="23"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-11" upper_limit="21"/>
                    <measurement group_id="O3" value="1.7" lower_limit="-7" upper_limit="22"/>
                    <measurement group_id="O4" value="2.5" lower_limit="-10" upper_limit="15"/>
                    <measurement group_id="O5" value="-2.4" lower_limit="-21" upper_limit="15"/>
                    <measurement group_id="O6" value="-0.3" lower_limit="-20" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-15" upper_limit="15"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-17" upper_limit="20"/>
                    <measurement group_id="O3" value="2.7" lower_limit="-9" upper_limit="18"/>
                    <measurement group_id="O4" value="1.5" lower_limit="-11" upper_limit="13"/>
                    <measurement group_id="O5" value="-1.8" lower_limit="-22" upper_limit="13"/>
                    <measurement group_id="O6" value="-1.2" lower_limit="-18" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="-12" upper_limit="14"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-19" upper_limit="16"/>
                    <measurement group_id="O3" value="3.3" lower_limit="-10" upper_limit="15"/>
                    <measurement group_id="O4" value="5.3" lower_limit="-10" upper_limit="21"/>
                    <measurement group_id="O5" value="0.2" lower_limit="-17" upper_limit="19"/>
                    <measurement group_id="O6" value="3.2" lower_limit="-16" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="-19" upper_limit="27"/>
                    <measurement group_id="O2" value="2.4" lower_limit="-16" upper_limit="21"/>
                    <measurement group_id="O3" value="5.0" lower_limit="-8" upper_limit="15"/>
                    <measurement group_id="O4" value="3.9" lower_limit="-12" upper_limit="23"/>
                    <measurement group_id="O5" value="0.5" lower_limit="-21" upper_limit="18"/>
                    <measurement group_id="O6" value="2.1" lower_limit="-18" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="-13" upper_limit="28"/>
                    <measurement group_id="O2" value="5.5" lower_limit="-13" upper_limit="32"/>
                    <measurement group_id="O3" value="5.5" lower_limit="-15" upper_limit="24"/>
                    <measurement group_id="O4" value="7.6" lower_limit="-12" upper_limit="28"/>
                    <measurement group_id="O5" value="2.4" lower_limit="-18" upper_limit="25"/>
                    <measurement group_id="O6" value="5.2" lower_limit="-15" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="-14" upper_limit="22"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-13" upper_limit="13"/>
                    <measurement group_id="O3" value="3.1" lower_limit="-6" upper_limit="17"/>
                    <measurement group_id="O4" value="2.0" lower_limit="-12" upper_limit="16"/>
                    <measurement group_id="O5" value="0.7" lower_limit="-26" upper_limit="15"/>
                    <measurement group_id="O6" value="0.4" lower_limit="-11" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="-12" upper_limit="25"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-21" upper_limit="18"/>
                    <measurement group_id="O3" value="1.6" lower_limit="-9" upper_limit="12"/>
                    <measurement group_id="O4" value="4.3" lower_limit="-10" upper_limit="20"/>
                    <measurement group_id="O5" value="-1.5" lower_limit="-28" upper_limit="19"/>
                    <measurement group_id="O6" value="1.3" lower_limit="-19" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 1h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="-16" upper_limit="26"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-18" upper_limit="15"/>
                    <measurement group_id="O3" value="1.6" lower_limit="-11" upper_limit="12"/>
                    <measurement group_id="O4" value="3.2" lower_limit="-12" upper_limit="19"/>
                    <measurement group_id="O5" value="-1.2" lower_limit="-31" upper_limit="29"/>
                    <measurement group_id="O6" value="0.4" lower_limit="-22" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 4h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="-14" upper_limit="24"/>
                    <measurement group_id="O2" value="2.3" lower_limit="-19" upper_limit="14"/>
                    <measurement group_id="O3" value="6.7" lower_limit="-7" upper_limit="25"/>
                    <measurement group_id="O4" value="3.4" lower_limit="-14" upper_limit="19"/>
                    <measurement group_id="O5" value="1.8" lower_limit="-22" upper_limit="15"/>
                    <measurement group_id="O6" value="2.3" lower_limit="-25" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 8h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="-16" upper_limit="26"/>
                    <measurement group_id="O2" value="3.5" lower_limit="-22" upper_limit="19"/>
                    <measurement group_id="O3" value="4.9" lower_limit="-16" upper_limit="19"/>
                    <measurement group_id="O4" value="3.8" lower_limit="-12" upper_limit="24"/>
                    <measurement group_id="O5" value="1.6" lower_limit="-21" upper_limit="23"/>
                    <measurement group_id="O6" value="2.6" lower_limit="-22" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 12h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="-17" upper_limit="34"/>
                    <measurement group_id="O2" value="7.5" lower_limit="-17" upper_limit="30"/>
                    <measurement group_id="O3" value="6.7" lower_limit="-15" upper_limit="19"/>
                    <measurement group_id="O4" value="5.4" lower_limit="-16" upper_limit="27"/>
                    <measurement group_id="O5" value="0.5" lower_limit="-23" upper_limit="16"/>
                    <measurement group_id="O6" value="5.1" lower_limit="-19" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate (HR) AUC(0-4h), Normalized by Time -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
        <description>Heart rate HR AUC(0-4h) normalized by time. Results are shown by treatment group, as change from baseline (in bpm).&#xD;
The HR AUC(0-4h) normalized by time is calculated based on the actual times, using the linear trapezoidal rule.&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate (HR) AUC(0-4h), Normalized by Time -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
          <description>Heart rate HR AUC(0-4h) normalized by time. Results are shown by treatment group, as change from baseline (in bpm).&#xD;
The HR AUC(0-4h) normalized by time is calculated based on the actual times, using the linear trapezoidal rule.&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.9" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.8" lower_limit="-1.0" upper_limit="2.6"/>
                    <measurement group_id="O3" value="2.7" lower_limit="1.4" upper_limit="4.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="1.7" upper_limit="4.2"/>
                    <measurement group_id="O5" value="-1.0" lower_limit="-2.8" upper_limit="0.7"/>
                    <measurement group_id="O6" value="0.3" lower_limit="-1.2" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.3" upper_limit="4.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.7" upper_limit="2.2"/>
                    <measurement group_id="O3" value="3.5" lower_limit="1.9" upper_limit="5.1"/>
                    <measurement group_id="O4" value="3.3" lower_limit="1.4" upper_limit="5.3"/>
                    <measurement group_id="O5" value="-0.1" lower_limit="-2.5" upper_limit="2.2"/>
                    <measurement group_id="O6" value="1.2" lower_limit="-0.9" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate (HR) Peak(0-4h), Normalized by Time -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
        <description>Heart rate (HR) peak(0-4h) normalized by time.&#xD;
Results are shown by treatment group, as change from baseline (in bpm).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.&#xD;
Definitions:&#xD;
HR=Heart rate; HR peak(0-4h)=The maximum observed value over 4 hours following dosing;</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate (HR) Peak(0-4h), Normalized by Time -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
          <description>Heart rate (HR) peak(0-4h) normalized by time.&#xD;
Results are shown by treatment group, as change from baseline (in bpm).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.&#xD;
Definitions:&#xD;
HR=Heart rate; HR peak(0-4h)=The maximum observed value over 4 hours following dosing;</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.1" upper_limit="6.2"/>
                    <measurement group_id="O2" value="4.4" lower_limit="2.2" upper_limit="6.6"/>
                    <measurement group_id="O3" value="6.5" lower_limit="4.7" upper_limit="8.3"/>
                    <measurement group_id="O4" value="7.5" lower_limit="5.9" upper_limit="9.0"/>
                    <measurement group_id="O5" value="2.9" lower_limit="0.8" upper_limit="5.0"/>
                    <measurement group_id="O6" value="5.1" lower_limit="3.3" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="3.8" upper_limit="8.5"/>
                    <measurement group_id="O2" value="4.8" lower_limit="2.5" upper_limit="7.1"/>
                    <measurement group_id="O3" value="8.3" lower_limit="6.2" upper_limit="10.3"/>
                    <measurement group_id="O4" value="7.3" lower_limit="5.4" upper_limit="9.2"/>
                    <measurement group_id="O5" value="4.4" lower_limit="1.6" upper_limit="7.1"/>
                    <measurement group_id="O6" value="5.2" lower_limit="2.9" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate (HR) AUC(0-4h) and Peak(0-4h), Normalized by Time -- Change From Pre-dose to Post Dose Day 14</title>
        <description>Heart rate (HR) AUC(0-4h) and HR peak(0-4h), normalized by time (in bpm).&#xD;
Results are shown as change from pre-dose on Day 14 (in bpm).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
Definitions:&#xD;
HR=Heart rate; HR AUC(0-4h)=Area under the curve between 0 and 4 h for heart rate; HR peak(0-4h)=The maximum observed value over 4 h after dosing;</description>
        <time_frame>Baseline, Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate (HR) AUC(0-4h) and Peak(0-4h), Normalized by Time -- Change From Pre-dose to Post Dose Day 14</title>
          <description>Heart rate (HR) AUC(0-4h) and HR peak(0-4h), normalized by time (in bpm).&#xD;
Results are shown as change from pre-dose on Day 14 (in bpm).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
Definitions:&#xD;
HR=Heart rate; HR AUC(0-4h)=Area under the curve between 0 and 4 h for heart rate; HR peak(0-4h)=The maximum observed value over 4 h after dosing;</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR AUC(0-4h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.7" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-1.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.4" lower_limit="-0.9" upper_limit="1.7"/>
                    <measurement group_id="O4" value="1.3" lower_limit="-0.1" upper_limit="2.7"/>
                    <measurement group_id="O5" value="-0.2" lower_limit="-1.7" upper_limit="1.3"/>
                    <measurement group_id="O6" value="0.9" lower_limit="-0.6" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR peak(0-4h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.6" upper_limit="5.4"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.2" upper_limit="6.9"/>
                    <measurement group_id="O3" value="5.1" lower_limit="3.3" upper_limit="6.9"/>
                    <measurement group_id="O4" value="5.3" lower_limit="3.8" upper_limit="6.7"/>
                    <measurement group_id="O5" value="4.3" lower_limit="2.3" upper_limit="6.2"/>
                    <measurement group_id="O6" value="4.8" lower_limit="3.1" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-lead Electrocardiogram (ECG) Parameter (QTcF Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
        <description>12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>12-lead Electrocardiogram (ECG) Parameter (QTcF Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
          <description>12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="-28" upper_limit="29"/>
                    <measurement group_id="O2" value="3.8" lower_limit="-5" upper_limit="29"/>
                    <measurement group_id="O3" value="2.7" lower_limit="-22" upper_limit="23"/>
                    <measurement group_id="O4" value="4.9" lower_limit="-27" upper_limit="24"/>
                    <measurement group_id="O5" value="-0.2" lower_limit="-30" upper_limit="25"/>
                    <measurement group_id="O6" value="1.4" lower_limit="-27" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="-44" upper_limit="19"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-29" upper_limit="27"/>
                    <measurement group_id="O3" value="3.9" lower_limit="-16" upper_limit="25"/>
                    <measurement group_id="O4" value="4.2" lower_limit="-21" upper_limit="31"/>
                    <measurement group_id="O5" value="0.4" lower_limit="-55" upper_limit="26"/>
                    <measurement group_id="O6" value="-0.9" lower_limit="-24" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="-39" upper_limit="24"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-30" upper_limit="25"/>
                    <measurement group_id="O3" value="0.8" lower_limit="-28" upper_limit="28"/>
                    <measurement group_id="O4" value="2.4" lower_limit="-17" upper_limit="22"/>
                    <measurement group_id="O5" value="-2.4" lower_limit="-42" upper_limit="16"/>
                    <measurement group_id="O6" value="-1.3" lower_limit="-30" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-25" upper_limit="15"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-14" upper_limit="31"/>
                    <measurement group_id="O3" value="0.6" lower_limit="-27" upper_limit="24"/>
                    <measurement group_id="O4" value="0.8" lower_limit="-18" upper_limit="23"/>
                    <measurement group_id="O5" value="-0.2" lower_limit="-20" upper_limit="25"/>
                    <measurement group_id="O6" value="-2.4" lower_limit="-37" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-26" upper_limit="25"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-21" upper_limit="32"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-25" upper_limit="21"/>
                    <measurement group_id="O4" value="1.1" lower_limit="-21" upper_limit="33"/>
                    <measurement group_id="O5" value="-1.5" lower_limit="-25" upper_limit="30"/>
                    <measurement group_id="O6" value="-2.2" lower_limit="-44" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-26" upper_limit="30"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-30" upper_limit="33"/>
                    <measurement group_id="O3" value="1.6" lower_limit="-20" upper_limit="28"/>
                    <measurement group_id="O4" value="5.8" lower_limit="-22" upper_limit="68"/>
                    <measurement group_id="O5" value="-2.3" lower_limit="-17" upper_limit="27"/>
                    <measurement group_id="O6" value="1.2" lower_limit="-46" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="-28" upper_limit="30"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-29" upper_limit="37"/>
                    <measurement group_id="O3" value="3.5" lower_limit="-28" upper_limit="31"/>
                    <measurement group_id="O4" value="10.4" lower_limit="-23" upper_limit="41"/>
                    <measurement group_id="O5" value="1.9" lower_limit="-29" upper_limit="22"/>
                    <measurement group_id="O6" value="1.7" lower_limit="-29" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 1h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="-19" upper_limit="23"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-45" upper_limit="37"/>
                    <measurement group_id="O3" value="1.9" lower_limit="-32" upper_limit="31"/>
                    <measurement group_id="O4" value="7.7" lower_limit="-25" upper_limit="44"/>
                    <measurement group_id="O5" value="0.9" lower_limit="-44" upper_limit="28"/>
                    <measurement group_id="O6" value="0.6" lower_limit="-36" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 4h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="-9" upper_limit="29"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-26" upper_limit="37"/>
                    <measurement group_id="O3" value="1.1" lower_limit="-33" upper_limit="30"/>
                    <measurement group_id="O4" value="5.0" lower_limit="-37" upper_limit="40"/>
                    <measurement group_id="O5" value="-1.1" lower_limit="-28" upper_limit="28"/>
                    <measurement group_id="O6" value="-1.1" lower_limit="-48" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 8h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="-21" upper_limit="30"/>
                    <measurement group_id="O2" value="1.7" lower_limit="-23" upper_limit="29"/>
                    <measurement group_id="O3" value="1.7" lower_limit="-35" upper_limit="28"/>
                    <measurement group_id="O4" value="2.2" lower_limit="-37" upper_limit="44"/>
                    <measurement group_id="O5" value="1.5" lower_limit="-28" upper_limit="34"/>
                    <measurement group_id="O6" value="0.4" lower_limit="-38" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 12h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="-15" upper_limit="29"/>
                    <measurement group_id="O2" value="1.7" lower_limit="-21" upper_limit="25"/>
                    <measurement group_id="O3" value="-0.9" lower_limit="-20" upper_limit="32"/>
                    <measurement group_id="O4" value="3.7" lower_limit="-17" upper_limit="34"/>
                    <measurement group_id="O5" value="-0.6" lower_limit="-22" upper_limit="20"/>
                    <measurement group_id="O6" value="-1.6" lower_limit="-36" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-lead Electrocardiogram (ECG) Parameter (PR Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
        <description>12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>12-lead Electrocardiogram (ECG) Parameter (PR Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
          <description>12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-33" upper_limit="22"/>
                    <measurement group_id="O2" value="1.6" lower_limit="-12" upper_limit="18"/>
                    <measurement group_id="O3" value="-1.3" lower_limit="-10" upper_limit="9"/>
                    <measurement group_id="O4" value="-3.6" lower_limit="-71" upper_limit="15"/>
                    <measurement group_id="O5" value="1.0" lower_limit="-13" upper_limit="15"/>
                    <measurement group_id="O6" value="3.2" lower_limit="-11" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-13" upper_limit="16"/>
                    <measurement group_id="O2" value="2.2" lower_limit="-16" upper_limit="21"/>
                    <measurement group_id="O3" value="-1.1" lower_limit="-27" upper_limit="17"/>
                    <measurement group_id="O4" value="-0.7" lower_limit="-66" upper_limit="13"/>
                    <measurement group_id="O5" value="0.4" lower_limit="-13" upper_limit="18"/>
                    <measurement group_id="O6" value="2.0" lower_limit="-11" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-14" upper_limit="11"/>
                    <measurement group_id="O2" value="1.6" lower_limit="-17" upper_limit="24"/>
                    <measurement group_id="O3" value="-1.5" lower_limit="-16" upper_limit="16"/>
                    <measurement group_id="O4" value="-4.0" lower_limit="-88" upper_limit="14"/>
                    <measurement group_id="O5" value="-1.6" lower_limit="-33" upper_limit="21"/>
                    <measurement group_id="O6" value="1.9" lower_limit="-13" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-16" upper_limit="23"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-14" upper_limit="20"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-16" upper_limit="10"/>
                    <measurement group_id="O4" value="-2.6" lower_limit="-74" upper_limit="10"/>
                    <measurement group_id="O5" value="-2.4" lower_limit="-29" upper_limit="16"/>
                    <measurement group_id="O6" value="-0.0" lower_limit="-13" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" lower_limit="-17" upper_limit="14"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-18" upper_limit="18"/>
                    <measurement group_id="O3" value="-3.8" lower_limit="-15" upper_limit="17"/>
                    <measurement group_id="O4" value="-3.0" lower_limit="-46" upper_limit="28"/>
                    <measurement group_id="O5" value="-2.6" lower_limit="-15" upper_limit="19"/>
                    <measurement group_id="O6" value="-1.7" lower_limit="-14" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-16" upper_limit="23"/>
                    <measurement group_id="O2" value="3.7" lower_limit="-17" upper_limit="25"/>
                    <measurement group_id="O3" value="-1.7" lower_limit="-22" upper_limit="15"/>
                    <measurement group_id="O4" value="-2.9" lower_limit="-53" upper_limit="18"/>
                    <measurement group_id="O5" value="0.1" lower_limit="-13" upper_limit="15"/>
                    <measurement group_id="O6" value="2.2" lower_limit="-15" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-24" upper_limit="22"/>
                    <measurement group_id="O2" value="4.5" lower_limit="-12" upper_limit="27"/>
                    <measurement group_id="O3" value="-1.5" lower_limit="-20" upper_limit="17"/>
                    <measurement group_id="O4" value="-3.1" lower_limit="-85" upper_limit="19"/>
                    <measurement group_id="O5" value="3.4" lower_limit="-15" upper_limit="26"/>
                    <measurement group_id="O6" value="5.1" lower_limit="-19" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 1h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-24" upper_limit="30"/>
                    <measurement group_id="O2" value="5.7" lower_limit="-13" upper_limit="35"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-19" upper_limit="25"/>
                    <measurement group_id="O4" value="-1.6" lower_limit="-93" upper_limit="19"/>
                    <measurement group_id="O5" value="5.2" lower_limit="-8" upper_limit="67"/>
                    <measurement group_id="O6" value="6.1" lower_limit="-14" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 4h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-28" upper_limit="14"/>
                    <measurement group_id="O2" value="2.5" lower_limit="-11" upper_limit="23"/>
                    <measurement group_id="O3" value="-2.5" lower_limit="-22" upper_limit="14"/>
                    <measurement group_id="O4" value="-3.2" lower_limit="-76" upper_limit="21"/>
                    <measurement group_id="O5" value="0.8" lower_limit="-18" upper_limit="20"/>
                    <measurement group_id="O6" value="1.3" lower_limit="-33" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 8h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-32" upper_limit="17"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-13" upper_limit="46"/>
                    <measurement group_id="O3" value="-3.2" lower_limit="-25" upper_limit="22"/>
                    <measurement group_id="O4" value="-5.4" lower_limit="-71" upper_limit="8"/>
                    <measurement group_id="O5" value="-1.1" lower_limit="-20" upper_limit="16"/>
                    <measurement group_id="O6" value="0.8" lower_limit="-28" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 12h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" lower_limit="-40" upper_limit="11"/>
                    <measurement group_id="O2" value="1.7" lower_limit="-22" upper_limit="59"/>
                    <measurement group_id="O3" value="-4.8" lower_limit="-24" upper_limit="19"/>
                    <measurement group_id="O4" value="-1.4" lower_limit="-27" upper_limit="27"/>
                    <measurement group_id="O5" value="0.1" lower_limit="-20" upper_limit="34"/>
                    <measurement group_id="O6" value="-0.3" lower_limit="-18" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-lead Electrocardiogram (ECG) Parameter (QRS Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
        <description>12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>12-lead Electrocardiogram (ECG) Parameter (QRS Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
          <description>12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-9" upper_limit="9"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-8" upper_limit="11"/>
                    <measurement group_id="O3" value="1.7" lower_limit="-6" upper_limit="8"/>
                    <measurement group_id="O4" value="1.1" lower_limit="-8" upper_limit="10"/>
                    <measurement group_id="O5" value="0.8" lower_limit="-7" upper_limit="7"/>
                    <measurement group_id="O6" value="1.3" lower_limit="-7" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-7" upper_limit="11"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-9" upper_limit="11"/>
                    <measurement group_id="O3" value="1.2" lower_limit="-6" upper_limit="13"/>
                    <measurement group_id="O4" value="1.6" lower_limit="-8" upper_limit="13"/>
                    <measurement group_id="O5" value="1.0" lower_limit="-5" upper_limit="8"/>
                    <measurement group_id="O6" value="1.4" lower_limit="-6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-6" upper_limit="13"/>
                    <measurement group_id="O2" value="2.1" lower_limit="-11" upper_limit="14"/>
                    <measurement group_id="O3" value="2.2" lower_limit="-6" upper_limit="18"/>
                    <measurement group_id="O4" value="2.1" lower_limit="-6" upper_limit="12"/>
                    <measurement group_id="O5" value="1.0" lower_limit="-6" upper_limit="11"/>
                    <measurement group_id="O6" value="1.1" lower_limit="-6" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-9" upper_limit="9"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-8" upper_limit="10"/>
                    <measurement group_id="O3" value="1.3" lower_limit="-6" upper_limit="13"/>
                    <measurement group_id="O4" value="0.5" lower_limit="-9" upper_limit="11"/>
                    <measurement group_id="O5" value="-0.2" lower_limit="-9" upper_limit="10"/>
                    <measurement group_id="O6" value="0.5" lower_limit="-10" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-9" upper_limit="12"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-13" upper_limit="8"/>
                    <measurement group_id="O3" value="1.0" lower_limit="-9" upper_limit="10"/>
                    <measurement group_id="O4" value="0.9" lower_limit="-9" upper_limit="9"/>
                    <measurement group_id="O5" value="0.4" lower_limit="-9" upper_limit="8"/>
                    <measurement group_id="O6" value="0.8" lower_limit="-8" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-9" upper_limit="13"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-12" upper_limit="10"/>
                    <measurement group_id="O3" value="-0.5" lower_limit="-10" upper_limit="10"/>
                    <measurement group_id="O4" value="1.7" lower_limit="-8" upper_limit="17"/>
                    <measurement group_id="O5" value="-0.9" lower_limit="-12" upper_limit="7"/>
                    <measurement group_id="O6" value="0.8" lower_limit="-8" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 30 min post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-7" upper_limit="14"/>
                    <measurement group_id="O2" value="1.6" lower_limit="-10" upper_limit="12"/>
                    <measurement group_id="O3" value="0.5" lower_limit="-7" upper_limit="11"/>
                    <measurement group_id="O4" value="2.4" lower_limit="-5" upper_limit="12"/>
                    <measurement group_id="O5" value="-0.3" lower_limit="-8" upper_limit="11"/>
                    <measurement group_id="O6" value="1.7" lower_limit="-6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 1h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-5" upper_limit="15"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-10" upper_limit="11"/>
                    <measurement group_id="O3" value="0.4" lower_limit="-7" upper_limit="9"/>
                    <measurement group_id="O4" value="2.3" lower_limit="-9" upper_limit="11"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-12" upper_limit="13"/>
                    <measurement group_id="O6" value="1.0" lower_limit="-10" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 4h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-10" upper_limit="15"/>
                    <measurement group_id="O2" value="1.8" lower_limit="-9" upper_limit="19"/>
                    <measurement group_id="O3" value="0.6" lower_limit="-7" upper_limit="9"/>
                    <measurement group_id="O4" value="2.8" lower_limit="-11" upper_limit="12"/>
                    <measurement group_id="O5" value="-0.2" lower_limit="-9" upper_limit="8"/>
                    <measurement group_id="O6" value="1.1" lower_limit="-6" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 8h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-11" upper_limit="15"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-10" upper_limit="12"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-11" upper_limit="12"/>
                    <measurement group_id="O4" value="1.4" lower_limit="-7" upper_limit="10"/>
                    <measurement group_id="O5" value="-0.8" lower_limit="-10" upper_limit="9"/>
                    <measurement group_id="O6" value="0.9" lower_limit="-12" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 12h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-8" upper_limit="15"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-13" upper_limit="10"/>
                    <measurement group_id="O3" value="0.3" lower_limit="-9" upper_limit="11"/>
                    <measurement group_id="O4" value="1.4" lower_limit="-6" upper_limit="17"/>
                    <measurement group_id="O5" value="-1.0" lower_limit="-9" upper_limit="8"/>
                    <measurement group_id="O6" value="0.5" lower_limit="-10" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Potassium -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
        <description>Serum potassium level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Potassium -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14</title>
          <description>Serum potassium level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 1.5h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.9" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-1.1" upper_limit="0.7"/>
                    <measurement group_id="O3" value="-0.08" lower_limit="-1.2" upper_limit="0.6"/>
                    <measurement group_id="O4" value="-0.17" lower_limit="-0.7" upper_limit="0.3"/>
                    <measurement group_id="O5" value="-0.06" lower_limit="-0.9" upper_limit="0.6"/>
                    <measurement group_id="O6" value="-0.18" lower_limit="-1.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 3h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.9" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.8" upper_limit="0.5"/>
                    <measurement group_id="O3" value="-0.23" lower_limit="-1.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="-0.28" lower_limit="-1.5" upper_limit="0.4"/>
                    <measurement group_id="O5" value="0.03" lower_limit="-0.7" upper_limit="0.9"/>
                    <measurement group_id="O6" value="-0.21" lower_limit="-1.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 5h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" lower_limit="-0.6" upper_limit="0.5"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.6" upper_limit="1.2"/>
                    <measurement group_id="O3" value="-0.12" lower_limit="-1.0" upper_limit="0.6"/>
                    <measurement group_id="O4" value="-0.19" lower_limit="-1.6" upper_limit="1.0"/>
                    <measurement group_id="O5" value="-0.04" lower_limit="-0.9" upper_limit="0.5"/>
                    <measurement group_id="O6" value="-0.20" lower_limit="-1.3" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 7h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.6" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-0.00" lower_limit="-0.9" upper_limit="0.7"/>
                    <measurement group_id="O3" value="-0.05" lower_limit="-0.8" upper_limit="0.8"/>
                    <measurement group_id="O4" value="-0.16" lower_limit="-1.8" upper_limit="0.6"/>
                    <measurement group_id="O5" value="0.04" lower_limit="-0.7" upper_limit="0.9"/>
                    <measurement group_id="O6" value="-0.14" lower_limit="-1.4" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 11h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.7" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.5" upper_limit="1.1"/>
                    <measurement group_id="O3" value="-0.08" lower_limit="-1.2" upper_limit="0.9"/>
                    <measurement group_id="O4" value="-0.10" lower_limit="-0.8" upper_limit="0.7"/>
                    <measurement group_id="O5" value="0.01" lower_limit="-1.0" upper_limit="0.6"/>
                    <measurement group_id="O6" value="-0.13" lower_limit="-1.4" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="-1.1" upper_limit="0.9"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-1.2" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.08" lower_limit="-0.9" upper_limit="0.9"/>
                    <measurement group_id="O4" value="-0.14" lower_limit="-1.5" upper_limit="1.3"/>
                    <measurement group_id="O5" value="0.05" lower_limit="-0.5" upper_limit="1.4"/>
                    <measurement group_id="O6" value="-0.13" lower_limit="-0.9" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 1.5h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.7" upper_limit="1.5"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-1.0" upper_limit="1.2"/>
                    <measurement group_id="O3" value="-0.10" lower_limit="-1.0" upper_limit="0.9"/>
                    <measurement group_id="O4" value="-0.23" lower_limit="-1.7" upper_limit="1.0"/>
                    <measurement group_id="O5" value="-0.03" lower_limit="-0.7" upper_limit="1.7"/>
                    <measurement group_id="O6" value="-0.15" lower_limit="-1.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 3h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.6" upper_limit="0.6"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-1.0" upper_limit="0.7"/>
                    <measurement group_id="O3" value="-0.13" lower_limit="-0.9" upper_limit="0.6"/>
                    <measurement group_id="O4" value="-0.24" lower_limit="-1.9" upper_limit="0.6"/>
                    <measurement group_id="O5" value="-0.00" lower_limit="-0.6" upper_limit="1.7"/>
                    <measurement group_id="O6" value="-0.15" lower_limit="-1.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 5h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.8" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-1.1" upper_limit="1.7"/>
                    <measurement group_id="O3" value="-0.01" lower_limit="-1.2" upper_limit="0.8"/>
                    <measurement group_id="O4" value="-0.26" lower_limit="-1.9" upper_limit="0.5"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-0.6" upper_limit="1.5"/>
                    <measurement group_id="O6" value="-0.15" lower_limit="-1.1" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 7h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.5" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.06" lower_limit="-0.8" upper_limit="1.2"/>
                    <measurement group_id="O3" value="0.09" lower_limit="-0.9" upper_limit="1.1"/>
                    <measurement group_id="O4" value="-0.19" lower_limit="-1.5" upper_limit="0.5"/>
                    <measurement group_id="O5" value="0.02" lower_limit="-0.7" upper_limit="1.3"/>
                    <measurement group_id="O6" value="-0.09" lower_limit="-1.1" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 11h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="-0.4" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-1.3" upper_limit="1.1"/>
                    <measurement group_id="O3" value="0.03" lower_limit="-1.0" upper_limit="1.1"/>
                    <measurement group_id="O4" value="-0.06" lower_limit="-1.4" upper_limit="1.2"/>
                    <measurement group_id="O5" value="0.01" lower_limit="-1.0" upper_limit="1.0"/>
                    <measurement group_id="O6" value="-0.02" lower_limit="-1.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Glucose -- Change From Baseline to Post-dose Day 1 and Day 14</title>
        <description>Serum glucose level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
        <time_frame>Baseline, Day 1, Day 14 post-dose</time_frame>
        <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A, CHF 1531 pMDI: 6 μg TDD</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B, CHF 1531 pMDI: 12 μg TDD</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C, CHF 1531 pMDI: 24 μg TDD</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D, CHF 1531 pMDI: 48 μg TDD</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>Treatment E, Matched placebo</description>
          </group>
          <group group_id="O6">
            <title>Treatment F</title>
            <description>Treatment F, Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Glucose -- Change From Baseline to Post-dose Day 1 and Day 14</title>
          <description>Serum glucose level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).&#xD;
For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.&#xD;
For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.</description>
          <population>Safety population:&#xD;
All randomized patients who received at least one dose of study treatment within the given period.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 1.5h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="-3.0" upper_limit="5.3"/>
                    <measurement group_id="O2" value="0.34" lower_limit="-4.9" upper_limit="11.7"/>
                    <measurement group_id="O3" value="0.57" lower_limit="-1.7" upper_limit="6.2"/>
                    <measurement group_id="O4" value="1.19" lower_limit="-1.2" upper_limit="8.4"/>
                    <measurement group_id="O5" value="0.47" lower_limit="-2.0" upper_limit="4.7"/>
                    <measurement group_id="O6" value="-0.06" lower_limit="-7.5" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 3h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="-3.3" upper_limit="4.8"/>
                    <measurement group_id="O2" value="0.54" lower_limit="-6.0" upper_limit="13.9"/>
                    <measurement group_id="O3" value="1.10" lower_limit="-2.1" upper_limit="4.8"/>
                    <measurement group_id="O4" value="1.79" lower_limit="-2.2" upper_limit="5.7"/>
                    <measurement group_id="O5" value="0.26" lower_limit="-3.1" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.39" lower_limit="-7.2" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 5h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="-3.2" upper_limit="6.4"/>
                    <measurement group_id="O2" value="1.12" lower_limit="-3.6" upper_limit="20.5"/>
                    <measurement group_id="O3" value="1.11" lower_limit="-1.0" upper_limit="4.2"/>
                    <measurement group_id="O4" value="1.58" lower_limit="-1.2" upper_limit="7.6"/>
                    <measurement group_id="O5" value="0.51" lower_limit="-5.1" upper_limit="10.9"/>
                    <measurement group_id="O6" value="0.44" lower_limit="-1.6" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 7h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="-2.6" upper_limit="4.8"/>
                    <measurement group_id="O2" value="0.42" lower_limit="-4.7" upper_limit="5.8"/>
                    <measurement group_id="O3" value="1.24" lower_limit="-1.3" upper_limit="6.5"/>
                    <measurement group_id="O4" value="1.37" lower_limit="-1.6" upper_limit="8.1"/>
                    <measurement group_id="O5" value="0.84" lower_limit="-1.6" upper_limit="10.4"/>
                    <measurement group_id="O6" value="0.61" lower_limit="-1.2" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 11h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="-4.1" upper_limit="6.4"/>
                    <measurement group_id="O2" value="1.08" lower_limit="-3.6" upper_limit="16.1"/>
                    <measurement group_id="O3" value="1.89" lower_limit="-1.6" upper_limit="6.5"/>
                    <measurement group_id="O4" value="1.42" lower_limit="-2.2" upper_limit="8.7"/>
                    <measurement group_id="O5" value="1.40" lower_limit="-1.1" upper_limit="6.7"/>
                    <measurement group_id="O6" value="0.90" lower_limit="-2.3" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" lower_limit="-8.7" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-3.8" upper_limit="2.9"/>
                    <measurement group_id="O3" value="0.49" lower_limit="-0.7" upper_limit="3.3"/>
                    <measurement group_id="O4" value="0.49" lower_limit="-0.8" upper_limit="10.0"/>
                    <measurement group_id="O5" value="0.37" lower_limit="-0.6" upper_limit="4.1"/>
                    <measurement group_id="O6" value="-0.03" lower_limit="-2.8" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 1.5h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="-7.0" upper_limit="9.5"/>
                    <measurement group_id="O2" value="0.26" lower_limit="-3.3" upper_limit="5.1"/>
                    <measurement group_id="O3" value="0.97" lower_limit="-1.3" upper_limit="4.8"/>
                    <measurement group_id="O4" value="1.21" lower_limit="-0.8" upper_limit="8.9"/>
                    <measurement group_id="O5" value="0.35" lower_limit="-2.0" upper_limit="3.2"/>
                    <measurement group_id="O6" value="-0.03" lower_limit="-4.8" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 3h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="-10.9" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.77" lower_limit="-2.1" upper_limit="4.5"/>
                    <measurement group_id="O3" value="1.31" lower_limit="-1.1" upper_limit="6.0"/>
                    <measurement group_id="O4" value="1.51" lower_limit="-1.7" upper_limit="9.9"/>
                    <measurement group_id="O5" value="0.25" lower_limit="-2.4" upper_limit="2.7"/>
                    <measurement group_id="O6" value="0.16" lower_limit="-7.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 5h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-10.8" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.90" lower_limit="-1.7" upper_limit="5.4"/>
                    <measurement group_id="O3" value="1.12" lower_limit="-1.9" upper_limit="4.7"/>
                    <measurement group_id="O4" value="1.16" lower_limit="-1.3" upper_limit="6.7"/>
                    <measurement group_id="O5" value="0.32" lower_limit="-1.8" upper_limit="4.4"/>
                    <measurement group_id="O6" value="0.53" lower_limit="-3.4" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 7h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-9.4" upper_limit="3.4"/>
                    <measurement group_id="O2" value="0.60" lower_limit="-2.5" upper_limit="7.6"/>
                    <measurement group_id="O3" value="0.73" lower_limit="-1.7" upper_limit="4.3"/>
                    <measurement group_id="O4" value="1.09" lower_limit="-0.7" upper_limit="12.0"/>
                    <measurement group_id="O5" value="0.25" lower_limit="-6.7" upper_limit="2.4"/>
                    <measurement group_id="O6" value="0.18" lower_limit="-4.6" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14; 11h post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="-7.9" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.30" lower_limit="-1.3" upper_limit="14.1"/>
                    <measurement group_id="O3" value="1.50" lower_limit="-0.5" upper_limit="5.8"/>
                    <measurement group_id="O4" value="1.47" lower_limit="-1.1" upper_limit="8.9"/>
                    <measurement group_id="O5" value="1.03" lower_limit="-2.7" upper_limit="3.8"/>
                    <measurement group_id="O6" value="0.68" lower_limit="-2.5" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first intake of study medication (Visit 2, Week 0) until study completion (Visit 10, Week 15) or study discontinuation.</time_frame>
      <desc>Safety population was used for the evaluation of treatment-emergent adverse event (TEAEs).&#xD;
The safety population is defined as all randomized patients who received at least one dose of study treatment within the given treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Treatment A CHF 1531 pMDI: 6 μg TDD</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Treatment B CHF 1531 pMDI: 12 μg TDD</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>Treatment C CHF 1531 pMDI: 24 μg TDD</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>Treatment D CHF 1531 pMDI: 48 μg TDD</description>
        </group>
        <group group_id="E5">
          <title>Treatment E</title>
          <description>Treatment E Matched placebo</description>
        </group>
        <group group_id="E6">
          <title>Treatment F</title>
          <description>Treatment F Formoterol fumarate IS Perforomist®: 40 μg TDD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Chiesi can publish and/or present any results of this study at scientific meetings, and to submit the clinical trial data to national and international Regulatory Authorities. Chiesi reserves the right to use such data for industrial purposes. Investigators will inform Chiesi before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation. Data from individual study sites must not be published separately.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Transparency</name_or_title>
      <organization>Chiesi Farmaceutici S.p.A.</organization>
      <phone>+ 39 0521 2791</phone>
      <email>clinicaltrials_info@chiesi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

